The bioavailability of sulforaphane from broccoli products in men and its epigenetic activity by Cramer, Jenna





THE BIOAVAILABILITY OF SULFORAPHANE FROM BROCCOLI PRODUCTS IN MEN 



















Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Food Science and Human Nutrition 
in the Graduate College of the 











Professor Emeritus John W. Erdman, Jr., Chair 
Professor Emerita Elizabeth H. Jeffery, Director of Research 
Assistant Professor Yuan-Xiang Pan 




Epidemiological data show a correlation between broccoli consumption and an anti-cancer 
benefit.  This benefit is attributed to the isothiocyanate sulforaphane (SF).  Sulforaphane is 
derived from the myrosinase-catalyzed hydrolysis of glucoraphanin.  Both glucoraphanin and 
myrosinase are present in fresh or lightly cooked broccoli and broccoli sprouts.  Like 
myrsoinase, gut microflora are capable of hydrolysis of glucoraphanin to SF, although to a much 
lesser extent than endogenous plant myrosinase (1, 2).  It is well established that when 
glucoraphanin is consumed in the absence of myrosinase, as is the case for heavily cooked 
broccoli, much of the cancer preventative potential is not availed (1, 3).  Similarly, many of the 
dietary glucoraphanin supplements on the market today lack myrosinase, and may not act as a 
source of SF.  However, the efficacy of these supplements in delivering SF has not been 
previously evaluated, neither has the potential for restoring the availability of SF by ingesting an 
exogenous source of myrosinase concomitantly with sources of glucoraphanin that are devoid of 
endogenous myrosinase.  
The mechanism of cancer protection by SF is multifaceted, but the best characterized involves 
the upregulation of detoxification enzymes through the nuclear factor (erythroid-derived 2)-like 
2/antioxidant response element pathway (4).  More recently, it was discovered that SF also 
inhibits cancer through epigenetic mechanisms, specifically by decreasing the activities of 
histone deacetylase and DNA methyltransferase enzymes (5, 6).  These effects were most 
pronounced at 10-15 µM SF, concentrations that are not typically obtained through dietary 
means.  Furthermore, it has not been previously determined whether the inhibition of DNA 
methyltransferase by SF correlates with increased expression of tumor suppressor genes.     
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The objective of this research was two-fold.  First, to determine the plasma and urine levels of 
SF and metabolites following human ingestion of a glucoraphanin supplement alone or in 
combination with a myrosinase-rich food source.  It was determined that the SF bioavailablity of 
a high-glucosinolate supplement that was devoid of myrosinase was enhanced by co-
consumption with a food source that contained myrosinase.  Specifically, plasma total 
isothiocyanate (ITC) concentration reached 2.86 ± 0.33 µM after the supplement was consumed 
with fresh broccoli sprouts whereas the peak plasma total ITC concentration after consumption 
of the glucoraphanin supplement did not reach significance over control meal or baseline values.   
The second objective was to evaluate the effects on DNA methylation and mRNA expression of 
cancer-related genes using physiologically attainable concentrations of SF similar to those 
identified in part one.  While the promoters of  P16, MGMT and MLH1 were unaffected by SF, 
DNA methylation at the P21 promoter was decreased by approximately 14% with a concurrent 
1.92 ± 0.32 fold increase in mRNA.  DNA methylation at the BAX promoter was decreased by a 
non-significant 11%, but was accompanied by a 1.64 ± 0.09 fold increase in mRNA, which did 
reach statistical significance.  The activity of histone deacetylase and DNA methyltransferase 
enzymes was also assessed at this physiological concentration of SF.  Histone deacetylase 
activity was unaffected, but DNA methyltransferase activity was decreased to 70.2 ± 9.8% of 
control after exposure to 5.0 µM SF. 
These results indicate that the availability of dietary SF can be enhanced by co-consumption of 
glucoraphanin with an exogenous source of myrosinase.  Separately, the results suggest that 
doses of SF attainable through diet may reduce the risk of cancer development partially by 
reducing the level of aberrant DNA methylation at the promoters of select tumor suppressor 
genes.  
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Cancer is the second leading cause of death in the United States, accounting for over 23% of 
deaths (1).  One in two men and one in three women will develop cancer in his or her lifetime 
(2).  Lifestyle choices, especially smoking, patterns of dietary consumption and physical 
exercise, are estimated to account for 10-70% of all cancers (2, 3). 
High rates of colon cancer are found in Westernized countries and evidence suggests that the 
causes of colon cancer are largely environmental, with the westernized diet being a key factor (4, 
5).  It is believed that colon cancer is mostly preventable by consuming an appropriate diet and 
other related factors (5).  Epidemiological evidence suggests that consumption of cruciferous 
vegetables can reduce the risk of several types of cancer, including colorectal cancer (6).  
Broccoli is a cruciferous vegetable and a rich source of many micronutrients in addition to the 
glucosinolate glucoraphanin (7-9).  Unfortunately, most Americans consume less than one 
serving per week, possibly due to the perception of an unpleasant flavor (10, 11).   
When the tissue of fresh broccoli is chewed, the enzyme myrosinase comes into contact with 
glucoraphanin and converts it to the cancer-preventative isothiocyanate sulforaphane (SF), which 
is partly responsible for the strong taste of fresh broccoli.  If the broccoli has been thoroughly 
cooked, myrosinase is rendered inactive and the mild tasting glucoraphanin remains intact.  As 
previously stated, some consumers may find the taste of fresh broccoli unappealing.  In fact, the 
taste of glucoraphanin (found in well-cooked broccoli) was preferred 81:19 compared to SF in a 
study that evaluated the taste preference between a SF containing or a glucoraphanin containing 
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beverage (11).  Dietary supplements are one way to overcome this obstacle.  However, broccoli 
supplements typically incorporate glucoraphanin as the source of bioactive SF and lack 
myrosinase, thus putting their efficacy into question.  It is a common public misconception that 
consumption of glucoraphanin, the inactive SF precursor from cooked broccoli or dietary 
supplements that have no myrosinase, provides health benefits comparable to those of SF.        
The two studies completed in Aim 1 tested the hypothesis that combining a glucosinolate 
preparation devoid of myrosinase, typical of both well cooked broccoli and many dietary 
supplements on the market, with a second product rich in myrosinase would enhance 
glucosinolate conversion and ITC absorption.  These are the first studies to examine a 
commercially available powdered broccoli preparation containing glucoraphanin, but lacking 
myrosinase and to examine effects of combining this glucoraphanin-rich broccoli preparation 
with an exogenous food source of myrosinase, broccoli sprouts.  The results show that 
combination improved SF availability, likely because the endogenous myrosinase from broccoli 
sprouts allowed early hydrolysis of glucoraphanin not only from the broccoli sprouts, but also 
from broccoli powder, resulting in early and more complete absorption of SF.  The effects of this 
combination open the door to development of products with enhanced chemo-protective 
potential.  The importance of these studies was realized as they have been followed-up by two 
larger studies from an independent research group (12, 13).   
In Aim 2, physiologically relevant concentrations of SF determined in Aim 1 and in other 
publications were used to evaluate the epigenetic activity of SF in colorectal cancer cells (14-16).  
Using physiologically relevant doses of SF, defined in this work as levels attainable in plasma 
through dietary consumption, is of interest as this approach mimics the situation that the majority 
of the population is exposed to this bioactive compound.  Colorectal cancer frequently includes a 
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number of epigenetic changes that occur throughout the development of cancer.  The 
gastrointestinal tract is constantly being exposed to food-derived compounds which may shift 
cellular balance towards harmful or beneficial outcomes depending on the foods consumed (5).  
It has been suggested that diet may be able to account for or prevent up to 80% of colon cancer 
incidence (17).  For these reasons, it is reasonable to postulate that colorectal cancer may be 
particularity amenable to reversal of aberrant epigenetic changes through dietary means.   
The cell line HCT 116 was selected for evaluation in Aim 2.  HCT 116 cells are tumorigenic 
colorectal carcinoma cells with a mutation of the Ras proto-oncogene and have been utilized 
previously for work examining the connection between bioactive food components and 
epigenetic modifications.  For the research conducted in Aim 2, the DNA methylation status of 
the O-6-methylguanine-DNA methyltransferase (MGMT), mutL homolog 1 (MLH1), cyclin-
dependent kinase inhibitor 2A (P16), BCL2-associated X protein (BAX) and cyclin-dependent 
kinase inhibitor 1A (P21) gene promoters were investigated.  Each of these genes has been 
reported to be upregulated by SF, with the exception of MLH1 which was selected due to its 
predominance as a gene often hypermethylated in colorectal cancer (18, 19).  Additionally, each 
gene selected for evaluation is involved in cancer, although they belong to different pathways 
(Figure 1.1).  Of particular interest is P21.  Stimulation of the nuclear factor (erythroid-derived 
2)-like 2 (Nrf2)/antioxidant response element (ARE) pathway is most commonly attributed with 
the reduction of cancer observed after exposure to SF.  However, P21 lacks an ARE; therefore, it 
is likely that upregulation of P21 by SF acts through a NRF2-independent mechanism, such as 
DNA demethylation and/or histone acetylation (20). 
In summary, combination of a glucoraphanin supplement with a source of myrosinase increases 
biomarkers of SF exposure in humans.  Elevated exposure to SF may reduce the risk for and 
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progression of cancers, including colorectal cancer.  Sulforaphane may contribute to the dietary 
protective effect of broccoli against colorectal cancer in part by decreasing DNA methylation 
and increasing expression of aberrantly silenced cancer-related genes at concentrations of SF that 
are attainable in humans through the diet.    
 
1.2 Specific aims 
Long Term Goal: To determine the bioavailability of SF from several broccoli products and the 
epigenetic activity of SF at physiological levels. 
Central Hypotheses:  
1) The bioavailiability of SF from a broccoli powder rich in glucoraphanin, but lacking 
myrosinase will be increased by simultaneously consuming broccoli sprouts containing 
myrosinase. 
2) At physiologically relevant concentrations, SF will result in decreased DNA methylation 
of the promoters of several hypermethylated genes in HCT 116 human colorectal 
carcinoma cells.  The demethylation will cause increased expression of these genes.      
 
Aim 1: To evaluate SF absorption and excretion following ingestion of a semi-purified 
broccoli powder rich in glucoraphanin and broccoli sprouts in healthy men. 
Hypothesis: The recovery of SF metabolites from urine and plasma will be greatest when 
additional myrosinase, in the form of broccoli sprouts, is provided concomitantly with the 
glucoraphanin-rich powder. 
1.1: (Clinical study 1) To determine urinary sulforaphane-N-acetylcysteine (SF-NAC) and 
plasma total isothiocyanates following consumption of glucoraphanin powder and air-dried 
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broccoli sprouts alone and in combination. 
1.2: (Clinical study 2) To determine urinary SF-NAC and a more kinetically complete data set of 
plasma total isothiocyanates following consumption of glucoraphanin powder and fresh broccoli 
sprouts alone and in combination. 
 
Aim 2: To determine the effect of SF on the DNA methylation profile and mRNA 
expression level of selected genes.  
Hypothesis: Sulforaphane will result in demethylation of the promoters of several genes selected 
based on their reported upregulation by SF.  The mRNA level of genes found to be demethylated 
by SF will increase following SF treatment.    
2.1: To determine the methylation status of the MGMT, MLH1, P21, BAX and P16 gene 
promoters in control and SF treated HCT 116 cells.  
2.2: To determine the associated changes in the mRNA expression levels of those genes from 
Aim 2.1 that responded robustly to SF exposure.  
2.3: To determine the effect of SF on histone deacetylase and DNA methyltransferase activity. 
 
1.3 References 
1. Centers for Disease Control and Prevention. www.cdc.gov/nchs/fastats/deaths.htm. Accessed 
08/2011.  
2. American Cancer Society. www.cancer.org. Accessed 08/2011.  
3. Doll R, Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the 
united states today. J Natl Cancer Inst. 1981 Jun;66(6):1191-308.  
4. Nystrom M, Mutanen M. Diet and epigenetics in colon cancer. World J Gastroenterol. 2009 
Jan 21;15(3):257-63.  
6 
5. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, 
physical activity, and the prevention of cancer: A global perspective. Washington DC: AICR; 
2007.  
6. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer 
risk: Epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007 Mar;55(3):224-36.  
7. USDA national nutrient database. www.nal.usda.gov/fnic/foodcomp/search. Accessed 
10/2011.  
8. Kurilich AC, Tsau GJ, Brown A, Howard L, Klein BP, Jeffery EH, Kushad M, Wallig MA, 
Juvik JA. Carotene, tocopherol, and ascorbate contents in subspecies of brassica oleracea. J 
Agric Food Chem. 1999 Apr;47(4):1576-81.  
9. Plumb GW, Price KR, Rhodes MJ, Williamson G. Antioxidant properties of the major 
polyphenolic compounds in broccoli. Free Radic Res. 1997 Oct;27(4):429-35.  
10. Engel E, Baty C, Le Corre D, Souchon I, Martin N. Flavor-active compounds potentially 
implicated in cooked cauliflower acceptance. J Agric Food Chem. 2002 Oct 23;50(22):6459-67.  
11. Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, Zhu J, Zhang YH, Chen YS, et al. 
Bioavailability of sulforaphane from two broccoli sprout beverages: Results of a short-term, 
cross-over clinical trial in qidong, china. Cancer Prev Res (Phila). 2011 Mar;4(3):384-95.  
12. Clarke JD, Hsu A, Riedl K, Bella D, Schwartz SJ, Stevens JF, Ho E. Bioavailability and 
inter-conversion of sulforaphane and erucin in human subjects consuming broccoli sprouts or 
broccoli supplement in a cross-over study design. Pharmacol Res. 2011 Nov;64(5):456-63.  
13. Clarke JD, Riedl K, Bella D, Schwartz SJ, Stevens JF, Ho E. Comparison of isothiocyanate 
metabolite levels and histone deacetylase activity in human subjects consuming broccoli sprouts 
or broccoli supplement. J Agric Food Chem. 2011 Sep 30.  
14. Gasper AV, Al-Janobi A, Smith JA, Bacon JR, Fortun P, Atherton C, Taylor MA, Hawkey 
CJ, Barrett DA, Mithen RF. Glutathione S-transferase M1 polymorphism and metabolism of 
sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr. 2005 
Dec;82(6):1283-91.  
15. Cramer JM, Jeffery EH. Sulforaphane absorption and excretion following ingestion of a 
semi-purified broccoli powder rich in glucoraphanin and broccoli sprouts in healthy men. Nutr 
Cancer. 2011;63(2):196-201.  
16. Cramer JM, Teran-Garcia M, Jeffery EH. Enhancing sulforaphane absorption and excretion 
in healthy men through the combined consumption of fresh broccoli sprouts and a 
glucoraphanin-rich powder. Br J Nutr. 2011 Sep 13:1-6.  
7 
17. Willett WC. Diet, nutrition, and avoidable cancer. Environ Health Perspect. 1995 Nov;103 
Suppl 8:165-70.  
18. Furukawa T, Konishi F, Masubuchi S, Shitoh K, Nagai H, Tsukamoto T. Densely methylated 
MLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers. 
Genes Chromosomes Cancer. 2002 Sep;35(1):1-10.  
19. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau 
SN. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. 
Cancer Res. 1998 Aug 1;58(15):3455-60.  
20. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection 







Figure 1.1.  Tumor suppression pathways of genes selected for evaluation of DNA methylation 







2.1 Cancer epidemiology and cruciferous vegetables 
Consumption of fruits and vegetables is inversely correlated with the risk of developing cancer 
(1).  In particular, epidemiological studies indicate a strong relationship between high intake of 
cruciferous vegetables and cancer prevention (2, 3).  In fact, crucifers appear to offer 
substantially greater reduction of cancer risk compared to other groups of fruits and vegetables 
(2-6).  Cruciferous vegetables are of the family Brassicaceae and are distinguished by the shape 
of their flowers in which the four petals resemble a cross.  Broccoli, cauliflower, cabbage, kale, 
Brussels sprouts, arugula, horseradish and mustard are examples of cruciferous vegetables.  High 
dietary intake of cruciferous vegetables is most consistently correlated with a decreased risk for 
cancers of the stomach, colon, rectum and lung, but evidence exists for a protective effect against 
other cancers including kidney, prostate, ovaries, bladder, pancreas and skin (2, 6-11).  
Cruciferous vegetables contain a unique class of sulfur containing organic compounds called 
glucosinolates.  Most research on the reduction of cancer risk by cruciferous vegetables is 
focused on glucosinolates and isothiocynates, glucosinolate hydrolysis products.  
Isothiocyanates, also known as mustard oils, are responsible for the spicy taste associated with 
crucifers (12).  Approximately 120 naturally occurring glucosinolates have been identified.  
Some of the most commonly studied include glucoraphanin, sinigrin, glucoerucin, glucoiberin, 




2.2 The bioactivity of broccoli   
Mature broccoli and broccoli sprouts are reported to offer protection against cardiovascular 
disease, hypertension, Helicobacter pylori infection, rheumatoid arthritis, macular degeneration, 
neurological conditions and cancer (14).  In particular, broccoli may be effective against cancers 
of the colon, rectum, bladder, breast and liver (15-18).  Broccoli provides fiber, vitamins, 
minerals and antioxidants including tocopherols, carotenoids and flavonoids, which all may play 
a role in the chemoprotective activity of broccoli (19-21).  Importantly, broccoli also contains 
glucosinolates with glucoraphanin (GRP) being the major glucosinolate present in broccoli.  
Glucoraphanin [4-(methylsulfinyl)butyl glucosinolate] likely plays a major role in the reduction 
of cancer risk that is attributed to broccoli consumption. 
Glucoraphanin is a naturally occurring, biologically inactive compound that is abundant in 
broccoli and broccoli sprouts.  Glucoraphanin gives rise to the biologically active isothiocyanate, 
sulforaphane (SF) [4-(methylsulfinyl)butyl glucosinolate], subsequent to hydrolysis by the 
endogenous thioglucoside glucohydrolase myrosinase (thioglucoside glucohydrolase; EC 
3.2.1.147).  It should be noted that SF is not the sole product that can form from the hydrolysis of 
GRP.  Nitriles and thiocyanates can also be produced as a result of GRP hydrolysis depending on 
factors including pH and the presence of metal ions and/or other proteins (22-24).  However, 
isothiocyanates and nitriles are the predominant hydrolysis products (Figure 2.1) (23).  
Sulforaphane is considered to be majorly responsible for the cancer preventative benefits of 
broccoli consumption (25).  Broccoli seeds and young sprouts contain higher amounts of GRP 
and have higher myrosinase activity than mature plants, making them a better source of SF (13).  
Although GRP is the predominant glucosinolate in broccoli, it must be acknowledged that other 
glucosinolates such as glucobrassicin and sinigrin are also present in broccoli and can produce 
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isothiocyanates that may provide benefits in addition to those of SF.  The research discussed in 
this literature review and presented in this dissertation is focused on SF, as SF is well known for 
its anti-cancer activity and is considered the primary anticarcinogen of broccoli (25).  
A review of published literature suggests that SF prevents and controls cancer by several 
mechanisms.  The induction of detoxification enzymes through the Kelch-like ECH-associated 
protein 1/nuclear factor (erythroid-derived 2)-like 2/antioxidant response element 
(Keap1/Nrf2/ARE) pathway is perhaps the best recognized (26).  In the basal state of a cell, the 
negative repressor protein Keap1 sequesters Nrf2 in the cytoplasm directing Nrf2 toward 
ubiquitylation and subsequent degradation (27-29).  When SF enters the cell, it reacts with 
cysteine residues of Keap1, preventing ubiquitylation of Nrf2.  Nrf2 then translocates to the 
nucleus where it binds to the ARE sequence in DNA.  The activation of gene transcription by 
Nrf2 upregulates expression of target genes including quinone reductase, glutathione transferases 
and antioxidant proteins (30).  Upregulation of these genes increases cellular protection through 
detoxification of harmful, potentially carcinogenic compounds. 
Other anti-carcinogenic mechanisms of SF include inhibition of phase 1 enzymes, inhibition of 
inflammation and induction of cell cycle arrest and apoptosis (26).  More recently, epigenetic 
mechanisms of cancer prevention and control by SF, such as inhibition of histone deacetylase 
and decreased DNA methylation, have been identified and are being investigated (31, 32).  These 
epigenetic mechanisms will be discussed in depth in section 2.5.    
 
2.3 The importance of myrosinase   
In mature broccoli and broccoli sprouts, myrosinase and the inactive SF precursor GRP are 
segregated in distinct cellular compartments (33).  Myrosinase and GRP interact upon damage to 
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the plant tissue, such as during crushing or chewing.  This interaction allows myrosinase to 
catalyze the hydrolysis of GRP to SF by cleavage of the -thioglucosidic bond.  It is therefore 
expected that SF metabolites will be detected in plasma soon after consumption of fresh broccoli 
or sprouts because the hydrolysis of GRP will occur in the upper gastrointestinal tract.   
Plant myrosinase is not the only means of producing SF.  Sulforaphane can also be formed by 
microflora of the mammalian colon that are capable of myrosinase-like activity (34, 35).  
Specifically, SF was detected following incubation of GRP in the cecum of rats, which is 
analogous to the human colon in terms of the location of gut microbes (35).  Additionally, 
recovery of GRP hydrolysis products was completely abolished in humans by treatment with 
antibiotics and mechanical cleansing of the colon (34).  These studies provide evidence that gut 
microbes are capable of GRP hydrolysis in the absence of myrosinase.  However, SF recovery 
after ingestion of GRP without myrosinase is much lower than recovery when myrosinase is 
supplied concomitantly with GRP, indicating that the hydrolyzing efficacy of gut microflora is 
much less than that of plant myrosinase (34, 36).  In the case where GRP products that lack 
myrosinase are the sole source of SF, such as well-cooked broccoli, broccoli supplements or 
broccoli powder lacking myrosinase, hydrolysis will be delayed until the GRP-containing meal 
reaches the colon and the microflora of the gut provide hydrolytic activity (34, 35, 37, 38).  In 
these instances, the extent of hydrolysis will also be reduced.  The consequence of late and 
incomplete hydrolysis by colonic microflora is a lower peak plasma level of cancer-preventative 





2.4 The bioavailability of sulforaphane from broccoli in humans   
The most commonly used method to establish SF bioavailability in human subjects is the 
measurement of SF metabolites in plasma and urine after consumption of a SF-containing or 
producing meal.  These methods are preferred over others due to the non-invasive methods of 
sample collection.  The cyclocondensation assay, which utilizes a derivatization of 
isothiocyanates and their metabolites for detection, as well as direct detection of sulforaphane-N-
acetylcysteine (SF-NAC) using HPLC are two common methods used in clinical studies to 
examine the bioavailability of SF in humans.   
 
The cyclocondensation reaction and measurement of SF metabolites in plasma  
Isothiocyanates and their dithiocarbamate metabolites (hereafter referred to as total ITC) react 
stoichiometrically with 1,2-benzenedithiol to produce 1,3-benzodithiole-2-thione, which can be 
detected at 365 nm (Figure 2.2) (12, 39).  This derivatization is referred to as the 
cyclocondensation reaction and has successfully been used to measure the very low 
concentrations of total ITC found in human plasma following a brassica meal (36, 40).  This 
assay is advantageous as it provides an overall measurement of total ITC exposure.  The 
limitation is that it does not allow for the differentiation between the isothiocyanate, 
isothiocyante –glutathione, -cysteine-glycine, -cysteine, or –N-acetylcysteine conjugates.  LC-
MS/MS techniques that are capable of detecting each isothiocyante and isothiocyanate-conjugate 
individually are available for studies that require this type of differentiation (41).  The 
disadvantage of these techniques is that the total ITC measurement is not provided.  Therefore, 
these techniques are advantageous only when a particular isothiocyanate or isothiocyanate 
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metabolite is being investigated.  These techniques are also associated with higher cost and a 
greater time requirement as a standard for each compound of interest must be prepared.  
 
Direct detection of SF-NAC in urine by HPLC 
Metabolites of SF accumulate in urine before being excreted from the body.  Therefore, the 
amount of SF metabolites present in urine following a brassica meal are much greater compared 
to the levels present in plasma.  For this reason, detection of individual metabolites in urine 
samples is possible using HPLC methods.  Sulforaphane-N-acetylcysteine is the predominant SF 
metabolite present in urine after exposure to SF and is often used as a marker of bioavailability 
(36, 41).     
Approximately 74% of dietary SF is absorbed in the jejunum (42).  After absorption, SF is 
conjugated to glutathione by glutathione transferases in the intestinal epithelium and liver (42).  
SF-glutathione is then sequentially metabolized to SF-cysteinyl-glycine and SF-cysteine (43).  
Finally, SF-cysteine is conjugated to SF-NAC by the activity of N-acetyltransferase in the kidney 
and excreted in urine (43).  Small amounts of SF and SF-cysteine are also excreted, but SF-NAC 
is the major SF metabolite appearing in urine (41).  Therefore, SF-NAC is often used as a marker 
of bioavailability. 
 
Clinical studies of SF bioavailability 
The metabolic fate of glucosinolates has been investigated following human ingestion of steamed 
broccoli, fresh broccoli, broccoli sprouts, preformed isothiocyanates from sprout homogenate, 
and GRP from broccoli sprout homogenate without myrosinase.  The inclusion of sufficient 
washout periods and glucosinolate-free diets during broccoli feeding studies ensures that the 
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major isothiocyanate measured in plasma or urine is SF and SF metabolites.  The half-life of SF 
is reported to be approximately 2 hours (40, 44).   
 
Plasma metabolites 
Because plasma concentrations of compounds relate to effects at the site of action, peak plasma 
levels of total ITC are measured as an indication of cancer-preventative potential from SF.  A 
higher peak plasma level of total ITC indicates an increased potential for cancer prevention.  
Peak plasma total ITC levels range between 0.07-7.3 µM after consumption of various broccoli 
products and preparations (36, 40, 41, 45, 46).  Most studies report a Cmax between 2-3 µM.  The 
Cmax of plasma total ITC is largely dependent on the dose of SF or GRP consumed, which varies 
with whether myrosinase is present.  For example, the peak plasma total ITC concentration 
following consumption of fresh broccoli was approximately three times higher than the 
concentration reached after an equimolar dose of GRP from well-steamed broccoli that lacked 
myrosinase (36).  Other factors that may influence the Cmax of plasma total ITC include 
variations of subject genotype, especially of the glutathione-S-transferase (GST) gene, and 
differences in gut microflora composition.  However, two recent studies from independent 
research groups indicated that polymorphisms in the GSTP1, GSTM1 and GSTT1 genes did not 
affect SF metabolism or excretion (47, 48).  Repeated dosing of broccoli does not lead to 
accumulation or higher plasma levels of SF over time (45).     
The time of peak plasma concentration is also dependent on whether the source of SF is 
preformed isothiocyanate or GRP.  In the case of GRP ingestion, the time of peak plasma 
concentration also depends on whether or not myrosinase is present.  Preformed isothiocyanates 
or GRP in the presence of myrosinase result in earlier peak plasma total ITC than GRP without 
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myrosinase (36, 40, 44).  Peak plasma total ITC concentration occurs approximately 1-2 h after 
consumption of fresh broccoli or preformed isothiocyanate (40, 41, 44, 45).  The peak plasma 
total ITC concentration is delayed to approximately 6 h post-consumption following ingestion of 
GRP without a source of myrosinase (36, 44).  Plasma total ITC return to baseline values by 24 h 
post-consumption regardless of the source of ITC, GRP or presence of myrosinase (36, 41, 44).      
 
Urinary metabolites 
The appearance and elimination profile of SF metabolites in urine closely mimics the pattern in 
plasma.  Glucoraphanin without myrosinase results in lower and delayed appearance of SF 
metabolites compared to preformed isothiocyanates or GRP with myrosinase present.  Conaway 
et al. found that excretion of urinary isothiocyanate metabolites was approximately three times 
greater from fresh broccoli than from well-steamed broccoli, where myrosinase had been heat-
inactivated leaving GRP to be hydrolyzed to SF by gut microflora (36).  A similar study found 
that the bioavailability of SF from fresh broccoli was 11 times greater than that from cooked 
broccoli (44).  Another study evaluated the appearance of total ITC in urine following ingestion 
of broccoli sprout homogenates that contained either 111 µmol preformed isothiocyanates or 
111µmol unhydrolyzed glucosinolates (49).  The authors found that excretion of urinary 
isothiocyanate metabolites was approximately 7 times greater after consumption of the 
preformed isothiocyanates than the unhydrolyzed glucosinolates (49).  Recovery from uncooked, 
intact fresh sprouts without added myrosinase was reported to be ~50% (49).  As seen in plasma, 
repeated dosing with either SF or GRP did not lead to an increase in daily urinary SF recovery 
(48).     
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Chewing of broccoli was shown to increase the bioavailability of SF from a plant matrix (49).  
Glucosinolate conversion to isothiocyanate was increased by 68% with thorough chewing of 
fresh, uncooked broccoli sprouts (49).  Additionally, it seems that the meal matrix that broccoli is 
served with does not affect the conversion of GRP to SF, but may have an impact if SF is 
ingested as a preformed isothiocyanate (50).  In this study, the absorption of preformed allyl 
isothiocyanate was 1.3 fold higher when consumed as part of a meat-containing meal than with a 
meal devoid of meat, but no difference in SF absorption was detected when broccoli was served 
with or without meat (50).  The body of work encompassing the effect of meal matrix on GRP to 
SF conversion and subsequent uptake in humans is comprised only of this single piece of work.  
Therefore, more research is needed before definitive statements can be made.    
As is the case with the time required to reach peak plasma total ITC concentration, the time 
required to reach peak urinary excretion of SF metabolites is also dependent on whether the 
source of SF is preformed isothiocyanate or GRP and if myrosinase is present.  Urinary excretion 
of SF metabolites reaches peak concentration 3-6 h after consumption of fresh broccoli, but is 
delayed until 6-12 h after consumption of GRP (44).  SF metabolites are almost completely 
eliminated from urine by 24 h post-consumption regardless of whether GRP was consumed in 
the absence or presence of myrosinase (36, 44). 
Overall, glucosinolate availability and excretion is dictated by conversion to isothiocyanate.  
Thus, myrosinase is a key factor to isothiocyanate bioavailability.  The result of GRP 
consumption without myrosinase is lower and delayed exposure to bioactive SF.  Exogenous 
myrosinase from white mustard or daikon radish has been used to hydrolyze GRP to SF ex vivo 
as a way to prepare preformed isothiocyanates or to quantify GRP (40, 51).  Our studies detailed 
in chapters 3 and 4 are the first to evaluate the possibility that myrosinase from a second food 
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source could provide hydrolytic activity to a food containing GRP, but lacking myrosinase in 
vivo.     
 
2.5 Epigenetic basis of cancer   
Epigenetics is defined as “the study of heritable changes in gene expression that occur 
independent of changes in the primary DNA sequence” (52).  Epigenetic mechanisms include 
DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs (52).  
Collectively, these elements are referred to as the epigenome.  The epigenome is responsible for 
regulating access to genetic information.  All cells in the body have identical DNA, but differ in 
their epigenetic landscape.  The epigenome is thus responsible for cellular diversity in an 
organism (52).  Improper epigenetic alterations, or epimutations, can significantly impact cancer 
development through activation or inhibition of various biological pathways, primarily by 
regulating access to genes.  Interestingly, it has been suggested that epigenetic changes, rather 
than genetic mutations, may be responsible for the silencing of as many as half of the tumor 
suppressor genes that are aberrantly silenced in cancer (53).  Thus, the packaging of the genome 
seems to be of equal importance to the genome itself in regulating cellular processes and 
contributing to the development and outcome of several chronic diseases. 
 
DNA methylation 
DNA methylation is catalyzed by a group of enzymes called DNA methyltransferases (DNMT).  
DNA methylatransferases act by transferring a methyl group from S-adenosylmethionine to the 
5-position of the pyrimidine ring of cytosine (54).  There are currently three known DNMT 
enzymes: two de novo methyltransferases (DNMT3A and 3B) and one maintenance 
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methyltransferase (DNMT1) (52, 55).  The de novo DNMTs are independent of DNA replication 
(52).  The maintenance DNMT has a preference for methylating hemimethylated DNA and acts 
during DNA replication, reproducing the methylation pattern of the parent strand (52).  However, 
this model may be oversimplified as both groups of DNMTs have been shown to be capable of 
some level of both maintenance and de novo methylation (56).   
Many cancers have an epigenetic basis whereby certain genes show an aberrantly high degree of 
promoter DNA methylation and an associated transcriptional silencing of expression (57).  In 
mammals, DNA methylation occurs most typically on the cytosine residues within CpG islands, 
which are areas of DNA with a high concentration of CpG dinucleotides and often located in the 
promoter region of genes.  In normal cells, most CpG sites throughout the genome are 
methylated, but islands of CpG sites in the promoter regions of genes remain unmethylated (52).  
In cancer cells, the DNA methylation pattern shifts to one characterized by global 
hypomethylation with site-specific hypermethylation of promoter CpG islands (52).  These 
changes lead to genome instability and silencing of tumor suppressor genes, which results in a 
condition of uncontrolled growth, accumulated DNA damage and resistance to cell death (Figure 
2.3) (52).   
The mechanisms by which changes in the DNA methylation pattern occur and specific genes are 
targeted for hypermethylation are not well understood (52).  One suggested mechanism involves 
the targeting of DNMT to specific genes by oncogenic transcription factors (58).  Another 
proposed mechanism is that a reversible DNA binding polycomb protein is replaced by more 
stable DNA methylation through recruitment of DNMT by the polycomb protein, leading to 
permanent silencing of tumor suppressor genes (59).  Yet another hypothesis is that a repressive 
epigenetic landscape can spread along DNA resulting in de novo DNA methylation and silencing 
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of tumor suppressor genes (60).  Additionally, a general elevation in the expression level of 
DNMT enzymes likely plays a role in the observed changes of DNA methylation in cancer (61).  
In fact, DNMTs have been reported to be overexpressed in a variety of cancers including those 
of the breast, colon, lung and prostate (62-65).  This may be due to loss or inhibition of the 
retinoblastoma protein, a tumor suppressor protein that is dysfunctional in nearly all cancers 
(66).  Retinoblastoma is a repressor of the transcription factor E2F, which upregulates 
transcription of genes including DNMT1 (66).  Therefore, when retinoblastoma is inactivated in 
cancer, the activity of E2F increases, resulting in elevated transcription of DNMT. 
Development of tools to decrease the expression and/or activity of DNMT enzymes has been a 
promising method for reducing the aberrant DNA methylation and thus permitting re-expression 
of tumor suppressor genes that are associated with cancer prevention.  Currently, two DNA 
demethylating drugs have been approved by the Food and Drug Administration for use in certain 
cancers.  These demethylating agents are 5-azacytidine and 5-aza-2’-deoxycytidine, which are 
detailed later in this section.  Other demethylating agents are under development.  The potential 
impact that dietary agents have on DNA methylation in cancer prevention is becoming of 
increasing interest.  This is discussed in section 2.6.    
 
Histone modifications 
Post-translational modification of histone tails also plays a regulatory role within a cell.  Histone 
tails can be methylated, acetylated, ubiquitylated, sumoylated, and phosphorylated (52).  
Together these modifications form a dynamic “histone code” that can regulate cellular activities 
by controlling the structure and activity of different regions of the chromosome (52).  Histone 
modifications can lead to activation or repression of gene expression depending on the type of 
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histone modification and where the modification is located (52).  Acetylation of histones is 
generally associated with transcriptional activation and is accomplished by histone 
acetyltransferase (HAT) enzymes (52).  Histone deacetylase (HDAC) enzymes remove acetyl 
groups from histone tails and are involved in gene silencing.  The opposing actions of HAT and 
HDAC determine the acetylation status of histones.  Histone deacetylases are often found to be 
overexpressed in cancer, resulting in a global loss of histone acetylation (67, 68).  By altering the 
acetylation state of histones, HDAC limits the access of transcriptional machinery to DNA, 
effectively silencing tumor suppressor genes (57, 69).  Therefore, in the presence of an HDAC 
inhibitor, histones are more acetylated and the gene of interest is activated.   
 
Epigenetic mechanisms act in concert 
In addition to exerting individual mechanisms of control, DNA methylation and histone 
modifications can act cooperatively.  Importantly, methylated DNA can recruit HDAC through 
methyl-CpG-binding proteins (70).  Conversely, histone modifying enzymes can recruit the 
DNA methylation machinery (71).  Therefore, HDAC and DNA methylation can work together 
to effectively silence genes. 
 
Colon cancer 
The global burden of cancer is increasing, largely because of population growth and increased 
life span, but also because of adopted habits including smoking, physical inactivity and 
consumption of a “westernized” diet (72).  Fortunately, risk reduction of some cancers is 
possible by educating the public to avoid smoking, exercise regularly and consume a 
nutritionally balanced diet rich in vegetables.   
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Worldwide, an estimated 1.2 million new cases of colorectal cancer were diagnosed and over 
600,000 deaths resulted from colorectal cancer in 2008 (72).  This puts colorectal cancer as the 
third and second most commonly diagnosed cancer and the fourth and third cause of death 
worldwide for males and females, respectively (72).  The incidence of colorectal cancer is 
rapidly increasing in geographical areas of historical low risk (72).  Undesirable changes in 
dietary patterns as well as increases in obesity and smoking are believed to contribute to this 
concerning trend (72). 
In the United States, the average overall cancer incidence increased between the years 1975 and 
2000 (73).  After 2000, the incidence rate began to decrease (73).  However, partly because the 
mortality rate from heart disease has steadily decreased since 1975, cancer is now the leading 
cause of death for individuals under 85 years of age (73).  According to the National Cancer 
Institute, colorectal cancer is the third most common cancer and third leading cause of cancer-
related deaths in the United States.  This is true for both men and women (73).  Ironically, the 
United States is currently the only country with a decreasing trend of colorectal cancer incidence 
and mortality in both men and women (72, 73).  This decrease is reflective of improvements in 
methods to detect and treat precancerous lesions (72, 73).   
Epigenetic changes often occur during the earliest stages of cancer development, including colon 
cancer, providing an opportunity for epigenetically targeted dietary compounds to impact cancer 
prevention (53, 74).  Evidence is accumulating supporting the hypothesis that epigenetic 
alterations play a major role in the initiation and progression of colorectal cancer (75, 76).   As is 
the case in many cancers, the earliest stages of colorectal cancer are characterized by a depletion 
of global DNA methylation, leading to increased genomic instability (77).  Hypermethylation of 
tumor suppressor and DNA repair gene promoter regions is also a predominant occurrence and 
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the most extensively characterized epigenetic abnormality of colorectal cancer (78).  In 
colorectal cancer, many genes showing hypermethylated promoter regions are involved in 
signaling events that regulate cell cycle, DNA repair/stability, apoptosis, adhesion, angiogenesis, 
invasion and metastasis, among others (78).  Dysregulation of histone acetylation and histone 
methylation also plays a well-established role in the progression of colorectal cancer (78).  
Additionally, both DNMT and HDAC enzymes are typically overexpressed in colorectal cancer, 
contributing to the state of gene silencing (64, 79, 80).  
Two drugs currently approved by the Food and Drug Administration for used in certain 
malignancies are 5-azacytidine and 5-aza-2’-deoxycytidine (81).  These drugs are nucleoside 
analogs that induce DNA hypomethylation by being incorporated into the growing DNA strand 
while it is synthesized during replication.  Once incorporated, the nucleoside analogs trap DNMT 
enzymes onto the DNA, rendering them unable to methylate DNA at other sites (52).  The 
trapping of DNMTs by these drugs leads to depletion of DNMT within the cells and results in 
successful inhibition of DNMT (52).  Therefore, 5-azacytidine and 5-aza-2’-deoxycytidine are 
effective therapeutic agents.  Unfortunately, these drugs commonly induce nausea, vomiting, 
diarrhea and myelosuppression (82).  They also have the potential to form mutagenic lesions, 
which if not repaired, can lead to additional cancers (82).  Thus, undesired side effects limit the 
treatment dose and duration of these drug therapies.  Preventative treatment with these drugs 
may be an option for high-risk patients, but in most cases, these hypomethylating drugs are too 
toxic to use for preventative measures (53).  Other nuceoside analogs as well as non-nucleoside, 
small molecule drugs are currently being investigated for effective DNMT inhibition with lower 
toxicity.     
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Because of direct contact, the digestive tract may be exposed to higher levels of dietary bioactive 
compounds compared to other organs.  Therefore, dietary factors with epigenetic targets may 
offer a unique opportunity for cancer prevention and/or reduced tumor progression through a role 
in maintaining normal epigenetic regulation of gene expression.  Due to lower toxicity, use of 
dietary factors rather than pharmaceutical agents may also help to minimize or eliminate the 
deleterious toxic side effects of present-day epigenetic therapies including hypomethylating 
drugs (83). 
 
2.6 Dietary anticarcinogens have epigenetic effects   
Several dietary bioactive components have been found to modulate the epigenome by altering 
DNA methylation and/or histone acetylation levels.  This is often accompanied by an increase in 
expression of tumor suppress or genes (54, 84-86).  Included among this group of bioactive 
dietary constituents are genistein, tea polyphenols/epigallacatechin 3-gallate, selenium and SF.  
Several differences have been observed concerning effective doses, responsive genes and 
responsive cell lines in regard to the epigenetic activity of the dietary bioactive agents that are 
discussed in the following subsections.  These differences demonstrate potential for substantial 
specificity of dietary components to target genes and cell lines, which is likely to be of 
importance for future applications.  These differences also highlight the need for properly 
designed animal and small clinical studies to confirm the observed in vitro effects and proposed 
mechanisms of action as well as to establish optimal doses and dosing frequencies before large 
scale clinical trials are commenced (87).  Finally, it should be understood that using 
concentrations relevant to dietary consumption is critical when attempting to evaluate possible 
dietary means to reduce the risk of cancer.  By studying concentrations that are attainable 
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through diet, results can be more easily translated to human use and can be used to establish non-
toxic treatment levels not only demonstrated through a history of safe use, but also through 
simple toxicity studies.      
 
Genistein 
DNA demethylation has been observed in a variety of cancer cell types following exposure to 
genistein, an isoflavone from soy.  A physiologically relevant, non-toxic dose of genistein was 
found to demethylate the promoter region of GSTP1 in the MDA-MB-468 human breast cancer 
cell line (85).  The demethylation was associated with restoration of expression of this previously 
silenced gene (85).  Interestingly, this dose of genistein did not affect DNA methylation of the 
retinoic acid receptor, beta (RAR-beta) gene promoter, suggesting specificity (85).  Genistein 
was also found to decrease DNA methylation and induce mRNA expression of WNT5a in 
SW1116 human colorectal adenocarcinoma cells (86).  Additionally, genistein effectively 
reversed DNA hypermethylation and restored expression of RAR-beta, P16 and MGMT in KSYE 
510 human esophageal squamous cell carcinoma cells (88).  Promoter demethylation and 
increased gene expression of RAR-beta was observed in LNCaP and PC3 human prostate cancer 
cells following genistein exposure, but the effective dose was much greater than that required to 
reverse methylation of the esophageal cancer cells, again suggesting specificity (88).  Genistein 
treatment was also associated with repressed transcription of the human telomerase reverse 
transcriptase (hTERT) gene (89).  Mechanistically, genistein was found to inhibit DNMT activity 
and protein expression (88-90).  Histone acetylation was also increased following exposure to 
genistein (90, 91).  The increase in acetylated histones occurred concurrently with both a 
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decrease in HDAC activity and an increase in histone acetyltransferase activity and expression 
(88, 90).    
 
Tea polyphenols/epigallocatechin-3-gallate 
Green tea, a popular beverage consumed worldwide, contains polyphenols that possess anti-
carcinogenic activities.  (-)-Epigallocatechin-3-gallate (EGCG) is the most abundant polyphenol 
found in green tea.  Exposure of LNCaP cells to EGCG or a combination of green tea 
polyphenols resulted in re-expression of silenced GSTP1 which correlated with demethylation of 
the GSTP1 promoter and inhibition of DNMT protein expression and activity (92).  The green 
tea polyphenol mix inhibited DNMT activity and increased GSTP1 expression more effectively 
than EGCG alone (92).  (-)-Eigallocatechin-3-gallate also increased mRNA and protein levels of 
silenced tumor suppressor genes P16 and P21 and decreased global DNA methylation as well as 
DNMT mRNA, protein and activity in A431 human epidermoid carcinoma cells (84).  Another 
study confirmed the reversal of hypermethylation at P16, RAR-beta, MGMT and hMLH1 by 
EGCG in KYSE 510 esophageal squamous cell carcinoma cells (93).  The loss of methylation 
correlated with increased mRNA and protein expression of these genes (93).  This study 
determined that EGCG inhibited DNMT activity through competitive inhibition by forming 
hydrogen bonds with proteins in the catalytic site of the DNMT enzyme (93).  Computational 
modeling of EGCG and DNMT confirmed the likelihood of a direct inhibitory interaction (94).  
In contrast to demethylation causing increased gene expression, demethylation of the promoter 
region of hTERT by EGCG resulted in decreased mRNA expression in MCF-7 breast cancer 
cells (95).  Interestingly, histone acetylation was decreased by EGCG treatment in this case (95).  
This paper proposed that DNA demethylation allowed the repressor complex including HDAC to 
26 
bind to the promoter of hTERT and resulted in decreased mRNA transcription and histone 
acetylation (95).   
Green tea polyphenols were also found to increase histone acetylation and decrease HDAC 
activity, mRNA and protein level (84, 92).  The changes in HDAC were accompanied by the 
changes in DNA methylation that were detailed in the previous paragraph (84).      
 
Selenium 
Selenium is a trace element and anti-oxidant that possesses anti-carcinogenic activity which may 
be partly due to alteration of the epigenome (54).  LnCaP cells treated every 48 h for 7 days with 
1.5 µM selenium in the form of sodium selenite resulted in DNA demethylation of the promoters 
and re-expression of the tumor suppressor genes GSTP1, adenomatous polyposis coli and 
cellular stress response 1 (96).  The effect was both dose and time dependent for GSTP1 (96).  
Conversely, a dose-dependent increase in DNA methylation of the P53 promoter was reported in 
Caco-2 cells after exposure to 0, 1, or 2 µM sodium selenite (97).  Sodium selenite did not affect 
promoter DNA methylation of P16 (97).  Sodium selenite effectively decreased the mRNA for 
DNMT1 and 3A with a reduction in protein level observed only for DNMT1 (96).  Other studies 
confirm the decreased levels of DNMT1 protein and activity (98, 99).  Additionally, HDAC 
activity was decreased with a concomitant increase in histone acetylation at H3-Lys 9 (96).  
Decreased histone methylation at H3-Lys 9 was also observed (96).  Increased acetylation and 
decreased methylation at H3-Lys 9 are both associated with activation of gene expression.  
Selenium also appears to protect cultured cancer cell lines as well as rodents from DNA 
hypomethylation (97, 99).  As discussed in the DNA methylation subsection of section 2.5, 
genomic DNA hypomethylation is a phenomenon characteristic of virtually all types of 
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neoplastic cells (100).  Collectively, these observations suggest that regulation of DNMT and 
alteration of the histone code may be important epigenetic mechanisms of chemoprevention by 
sodium selenite and other selenium compounds.  Interestingly, broccoli has the capacity to 
accumulate selenium when grown in an environment enriched with selenium (101, 102).  The 
potential health benefits of this interaction will be discussed later in the subsection titled 
Combination diets and therapies.   
 
Sulforaphane  
Sulforaphane has repeatedly been demonstrated to inhibit HDAC activity in a variety of cell 
types including colorectal, breast and prostate cancer cells (31, 32, 80).  In all cases, inhibition of 
HDAC activity was associated with an increase in histone acetylation levels.  It is interesting to 
evaluate the research discussed in this section bearing in mind that SF concentrations over        
~7 µM do not carry relevance to dietary SF (46).   
A 15 µM dose of SF inhibited HDAC activity in prostate cancer cells and increased histone 
acetylation at the P21 and BAX gene promoters, which was accompanied by increased protein 
expression of these genes (80).  Sulforaphane also dose dependently inhibited HDAC activity in 
a colorectal carcinoma cell line (31).  In this study, activity of HDAC was significantly 
decreased by 3 µM SF, although the effect was most pronounced with 15 µM SF treatment (31).  
In addition to inhibition of HDAC activity, an increase in histone acetylation and P21 protein 
expression was also observed at a concentration of 15 µM SF (31).  Using molecular modeling, 
the mechanism of HDAC inhibition by SF was hypothesized to be direct inhibition by the SF 
metabolite SF-cysteine at the active site of the HDAC enzyme (31).  In support of this 
hypothesis, inhibition of HDAC activity was fully reversed 18 h after SF was removed from the 
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culture medium of cells that had been exposed to SF for 6 h, demonstrating that SF or a 
metabolite of SF must be present to maintain HDAC inhibition (79).  While some researchers 
report that HDAC protein levels remain unaltered with only the activity of HDAC being 
influenced by SF (31), other reports have claimed that HDAC protein levels decrease in response 
SF (79).  The discrepancy between these observations was not due to the dose used as both 
studies utilized 15 µM SF.  However, the duration of exposure may be of importance.  Myzak et 
al. assayed HDAC protein expression 47 h after exposure to SF and saw no change in protein 
level (31) whereas Rajendran et al. assayed 24-36 h post-exposure and saw decreased HDAC 
protein expression (79).  The cell type used may have also been a factor.  Myzak et al. used 
human embryonic kidney 293 cells whereas Rajendran et al. used HCT 116 colon cancer cells 
(31, 79).  Interestingly, the observed decrease in HDAC protein expression may have actually 
been the result of an increase in HDAC protein of the vehicle-treated control cells.  In fact, the 
authors reported that HDAC activity in vehicle-treated control cells increased while activity in 
SF treated cells remained unchanged over time (79).   Another group, using breast cancer cells, 
reported that SF had no effect on histone acetyltransferase activity (32).   Therefore, it appears 
that SF may increase the acetylation level of histones through an inhibition of HDAC activity, 
independent of any change in histone acetyltransferase.  Whether alteration of HDAC protein 
expression plays a role in the observed decrease in HDAC activity is not established.  Overall, 
the mechanism by which SF results in decreased HDAC activity is not yet fully understood.  
One animal and one human study have examined the inhibition of HDAC by SF (80, 103).  Mice 
treated orally with a single 10 µmol dose of SF showed significant inhibition of HDAC activity 
and increased histone acetylation in the colonic mucosa 6 h after dosing (80).  Protein expression 
of p21 was unchanged at 6 h, but was doubled at the 24 and 48 h measurements (80).  Daily 
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consumption of 6 µmol SF/day for 10 weeks resulted in a trend for increased histone acetylation 
and p21 expression in the ileum, colon, prostate and peripheral blood mononuclear cells (80).  
However, the only significant changes were for histone acetylation and p21 expression in 
mononuclear cells and for p21 expression in the ileum (80).  Inhibition of HDAC activity in the 
prostate was also significant (80).  Tumor development was suppressed in this mouse model and 
histone acetylation was increased in colonic polyps (80).  The promoters for p21 and bax showed 
a trend toward enrichment with acetylated histones in the ileum and colon of SF treated mice, but 
increases were only significant in the ileum (80).  Protein expression of bax was increased in 
ileal, but not colonic polyps of SF treated mice (80).  It was not reported whether the protein 
expression of p21 was measured in polyps.  In another study, daily dietary treatment with        
7.5 µmol SF suppressed the growth of prostate cancer xenographs in nude mice (103).    Histone 
deacetylase activity was also decreased in the xenographs, prostates and mononuclear blood cells 
with a trend towards increased global histone acetylation and expression of bax protein (103).  
Finally, a single 600 µmol dose of SF given to human subjects through the consumption of 
broccoli sprouts inhibited HDAC activity in peripheral blood mononuclear cells 3 h post-
consumption (103).  The inhibition of HDAC activity was no longer significant 6 h post-
consumption (103).  Histone deacetylase activity returned to baseline level by 24 h (103).  
Overall, these results demonstrate that dietary SF inhibits HDAC activity in vivo. 
A previous investigation of gene expression changes in Caco-2 cells after exposure to SF 
revealed an approximately 2-fold decrease of DNMT1 mRNA (104).  However, these cells were 
treated with 50 µM SF, a very high dose, which may have had unintended and/or non-specific 
effects on cellular activities.  It was recently reported that 5 and10 µM SF downregulated 
DNMT1 and DNMT3a protein expression and resulted in decreased DNA methylation of the 
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hTERT gene in human breast cancer cells (32).  The effects were more robust with 10 µM SF 
treatment compared to 5 µM SF (32).  Contrary to the typical association of DNA methylation 
and increased gene expression, the observed DNA demethylation in this study correlated with 
repression of the gene of interest (32).  
 
Combination diets and therapies 
Whereas consuming a single bioactive component may prevent or reverse epimutations, there is 
potential to synergistically or additively enhance the effect by combining dietary bioactive 
components together or with drugs targeted to the epigenome.  Combinations of dietary agents 
may provide enhanced health benefit by affecting different epigenetic mechanisms of cancer 
protection.  Combining dietary agents with pharmaceuticals may allow for lower doses of 
potentially toxic drugs to be used, or for enhanced efficacy through targeting a variety of 
mechanisms.     
It is well established that combining drugs targeted to different epigenetic modifications has 
beneficial outcomes in cancer studies.  For example, the combination of the DNMT inhibitor 5-
aza-2’-deoxycytidine with HDAC inhibitors such as valproic acid or trichostatin A has shown 
promising synergistic effects in clinical and non-clinical trials (105-108).  Combining 5-aza-2’-
deoxycytidine with conventional chemotherapeutic agents has also shown encouraging results in 
clinical trials, but further research is needed (109-111).     
The potential for enhanced chemoprevention through the combination of bioactive dietary 
factors has already been realized.  It was found that combining tomato and broccoli reduced the 
development of prostate tumors to a greater extent than either tomato or broccoli alone (112).  
The combination of SF with selenium synergistically increased the activity of thioredoxin 
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reductase in a cell culture model using human hepatoma cells (113).   Additionally, broccoli 
enriched with selenium induced glutathione peroxidase activity while broccoli without selenium 
enrichment did not affect glutathione peroxidase activity (114).  The synergistic effect between 
broccoli and selenium was also evident in rat models where selenium enriched broccoli or 
broccoli sprouts resulted in fewer mammary tumors and aberrant colon crypts compared to 
selenium with or without low-selenium broccoli (101).  Whereas these studies demonstrate that 
foods and/or food components can be combined for enhanced efficacy in cancer risk reduction, 
few data exist that describe an additive or synergistic effect on cancer-related epigenetic 
endpoints in response to food-food or food-drug combinations.  In a cell culture model, SF plus 
trichostatin A increased acetylated histones H3 and H4 to a greater extent than either treatment 
alone (31).  Additionally, SF plus trichostatin A inhibited HDAC activity without affecting 
HDAC protein expression to any greater extent than SF or trichostatin A alone (31).  A 
synergistic effect on the suppression of hTERT was observed after co-treatment with genistein 
and 5-aza-2’-deoxycytidine (89).  In a separate study, combination of genistein with either 
trichostatin A or 5-aza-2’-deoxycytidine resulted in increased mRNA expression of RAR-beta 
and P16 to a greater extent than individual treatments (88).  Additionally, combination of 
genistein with SF enhanced the expression of RAR-beta, P16 and MGMT in a synergistic or 
additive manner (88).  Epigenetic endpoints such as DNA methylation and histone acetylation 
were not assessed in this study, but this is an important next step for establishing the 
mechanism(s) by which the expression of these genes were increased in response to the 
combination treatments utilized in this study.  Despite the limited size of the body of information 
pertaining to epigenetic effects on cancer through the combination of dietary bioactive 
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components, either in a food-food or food-drug combination, the need to conduct these types 
studies has been recognized (54, 55).    
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Figure 2.1.  The myrosinase catalyzed hydrolysis of glucoraphanin leads to the production of 









Figure 2.2.  Isothiocyanates and isothiocyanate metabolites react with 1,2-benzenedithiol to produce 1,3-benzodithiole-2-thione, which 








Figure 2.3.  DNA methylation of the promoter region of tumor suppressor genes in normal cells 
and tumor cells.  In normal cells, the promoter region of tumor suppressor genes is not 
methylated, allowing for gene transcription (upper panel).  In tumor cells, the promoter region of 
tumor suppressor genes can become aberrantly hypermethylated through the activity of DNMT 







Sulforaphane Absorption and Excretion Following Ingestion of a Semi-Purified 
Broccoli Powder Rich in Glucoraphanin and Broccoli Sprouts in Healthy Men 
(Cramer and Jeffery. Nutr Cancer. 2011;63(2):196-201.)   
 
3.1 Introduction  
Sulforaphane (SF), an isothiocyanate derived from the hydrolysis of glucoraphanin found 
naturally in broccoli, is considered responsible for the cancer preventative benefits of broccoli 
consumption.  The inactive precursor glucoraphanin is hydrolyzed to SF by the thiohydrolase 
myrosinase, found endogenously in broccoli and broccoli sprouts, or by microflora present in the 
colon (1).   
A few small clinical studies have examined the bioavailability of SF in humans.  The major 
metabolite of SF appearing in urine, SF-N-acetylcysteine (SF-NAC), is often used as a marker of 
bioavailability, although it is not the only metabolite present in urine (2, 3).  Isothiocyanates and 
their dithiocarbamate metabolites (hereafter referred to as total ITC) react stoichiometrically with 
1,2-benzenedithiol to produce 1,3-benzodithiole-2-thione, which can be detected at 365 nm (4, 
5).  This cyclocondensation reaction has successfully been used to measure the very low 
concentrations of total ITC found in human plasma following a brassica meal (6, 7).          
The metabolic fate of glucosinolates has been investigated following human ingestion of steamed 
or fresh broccoli (6).  Excretion of urinary ITC metabolites was approximately three times 
greater from fresh broccoli than from steamed, where myrosinase had been heat-inactivated 
leaving glucoraphanin to be hydrolyzed to SF by gut microflora (6).  A similar study evaluated 
appearance of total ITC in urine following ingestion of broccoli sprouts that had been either 
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completely hydrolyzed to ITC using exogenous myrosinase or contained only glucosinolates 
(myrosinase destroyed by boiling) (8).  They found that 90% of the preformed ITC and only 12% 
of the glucosinolate dose was recovered as total ITC in urine (8).  The fate of the remaining 
glucosinolates was not determined.  Recovery from uncooked sprouts without added myrosinase 
was 50% (8).  The study concluded that glucosinolate availability and excretion is dictated by 
conversion to ITC, and that myrosinase contributed to ITC bioavailability in sprouts (8).                
It is a common public misconception that consumption of glucoraphanin, the inactive SF 
precursor, from well-cooked broccoli or dietary supplements that have no myrosinase provides 
health benefits comparable to those of SF.  Here we tested the hypothesis that combining a 
glucosinolate preparation devoid of myrosinase, typical of many dietary supplements on the 
market, with a second product rich in myrosinase would enhance glucosinolate conversion and 
ITC absorption.  Four healthy human males were provided two broccoli products, alone or in 
combination; dried broccoli sprouts containing myrosinase and a broccoli powder rich in 
glucoraphanin, but lacking myrosinase.  This is the first study to examine a commercially 
available powdered broccoli preparation containing only glucoraphanin and to examine effects of 
combining this glucoraphanin-rich broccoli preparation with an exogenous food source of 
myrosinase, broccoli sprouts.  The results show that combination improved availability, opening 
the door to development of products with enhanced chemo-protective potential.   
 
3.2 Methods  
All chemicals were purchased from Sigma Chemical, St. Louis, MO unless stated otherwise.  
Air-dried broccoli sprouts and broccoli powder were a gift from Caudill Seed, Inc., Louisville, 
KY.   
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Human subjects study population.  Four healthy men of normal body weight, ages 18-30 
years, were recruited by fliers at the University of Illinois at Urbana-Champaign.  All subjects 
completed baseline questionnaires regarding dietary, tobacco and other drug or supplement use.  
All subjects signed informed consent documents before participating in the study.  The study was 
approved by the University of Illinois Institutional Review Board in October 2007 and took place 
November 27-December 8, 2007. 
 
Study design, meal administration and sample collection.  Subjects were randomly 
assigned to a four by four crossover design.  Meals were given on Tuesdays and Fridays 
resulting in a two or three day washout between meals; the half life for SF is reported as 
approximately 2 h (7, 9).  Subjects were given a list of foods known to contain glucosinolates 
and asked to avoid these foods for three days prior to and during the entire duration of the study.  
Subjects were also requested to avoid use of dietary supplements and more than two alcoholic 
beverages per day during the study.   
The morning of each trial, subjects were instructed to ingest a meal according to the crossover 
design.  Meals included two grams of ground, air-dried broccoli sprouts or broccoli powder alone 
or in combination (2 g of sprouts plus 2 g of powder) added to one cup dry cereal (Go Lean 
Crunch, Kashi Company, La Jolla, CA) and ½ cup plain fat free yogurt (Stonyfield Farm, 
Londonderry, NH).  The control meal included cereal and yogurt only.  Blood (20 mL) was 
drawn into EDTA (for cyclocondensation) and/or Lithium Heparin (for liver panel) vacutainer 
tubes (BD, Franklin Lakes, NJ) immediately prior to ingestion of each meal (0 h), and at three 
and 24 h following the meal.  Plasma was immediately prepared by centrifugation and stored at   
-80
º
C until analyzed.  Urine samples were collected at baseline (0 h), 0-6, 6-12 and 12-24 h after 
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meal consumption.  Baseline urine samples were kept on ice and ascorbic acid was added to the 
urine samples at 1 g/L urine no later than one hour following collection.  All other urine samples 
were collected into 500 mL bottles containing 0.5 g ascorbic acid.  Subjects were instructed to 
store samples in a cooler provided and return them the following morning at the 24 h blood draw.  
Samples were then stored at -80ºC until analyzed.    
 
Sulforaphane analysis.  Air-dried broccoli sprouts were ground using a coffee grinder.  In 
triplicate, ground broccoli sprouts (50 mg) were then added to 1.6 mL distilled H2O, vortexed, 
and left to hydrolyze in the dark for 24 hours.  The mixture was then centrifuged for 5 minutes at 
14,000 x g and filtered through a 0.45 µm nylon filter.  The supernatant was diluted 5-fold with 
distilled H2O and an internal standard of benzyl isothiocyanate was added.  In triplicate, broccoli 
powder was hydrolyzed in the same manner as broccoli sprouts described above except that     
0.8 U white mustard myrosinase was added.  The analysis of the broccoli powder was also 
conducted in the absence of added myrosinase to confirm the necessity of myrosinase in the 
conversion of glucoraphanin to SF.  Isothiocyanates were extracted into dichloromethane for 
analysis by gas chromatography.  Briefly, 1 µL extract was injected onto an Agilent 6890N gas 
chromatography system equipped with single flame ionization detection (Agilent Technologies, 
Santa Clara, CA).  Samples were separated using a 30 m x 0.32 mm J&W HP-5 capillary column 
(Agilent Technologies). After an initial hold at 40ºC for 2 min, the oven temperature was 
increased by 10ºC/min to 260ºC and held for 10 min.  Injector temperature was 200ºC; detector 
temperature was 280ºC.  Helium carrier gas flow rate was 25 mL/min.  Data output was analyzed 
by Agilent ChemStation software and compared to SF (LKT Laboratories, St. Paul, MN) and 
benzyl isothiocyanate standard curves.  
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Hepatic function panel.  Blood samples were collected in Lithium Heparin tubes and 
centrifuged at 1000 x g for 30 minutes.  Plasma was collected and stored frozen at -80ºC in the 
dark until routine hepatic function panel analysis by Provena Covenant Medical Center (Urbana, 
IL).   
 
Plasma isothiocyanate analysis.  Blood samples collected in EDTA tubes were centrifuged 
at 1000 x g for 30 minutes.  Plasma was collected and analyzed using a slight modification of the 
cyclocondensation method previously described (7).  Briefly, 200 L of 100 mmol/L potassium 
phosphate buffer and 400 L of 20 mmol/L 1,2-benzenedithiol were combined with 200 L 
plasma in a 4.0 mL sealable glass vial.  The mixture was incubated for two hours at 65ºC, cooled 
to room temperature and centrifuged at 10,000 x g for two minutes.  The supernatant (100 µL) 
was injected onto an analytical C18 reverse-phase column (ES Industries Marvel ODS-3, 5 m, 
250 x 4.6 mm, West Berlin, NJ) attached to a Waters HPLC system (Waters, Milford, MA).  The 
solvent system was operated isocratically with 80% methanol/20% water at a rate of 1.0 mL/min.  
A five-minute time interval was assigned for column washing between sample injections.  The 
cyclocondensation product, 1,3-benzodithiole-2-thione, was analyzed by absorption at 365 nm.  
For quantification, the peak area of 1,3-benzodithiole-2-thione (eluting between 10-11 minutes) 
was integrated using Empower Pro software (Waters) and compared to a standard developed by 
reacting known concentrations of pure allyl isothiocyanate with 1,2-benzenedithiol.   
 
Urinary N-acetylcysteine conjugate analysis.  Urine samples were analyzed as previously 
described (6, 10).  The filtered urine (50 µL) was analyzed by HPLC using a Hypersil C18 ODS 
column (10 m, 250 x 4.6 mm, Phenomenex, Torrance, CA) and detected at 254 nm using the 
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Waters HPLC system described above.  A gradient solvent system with a flow rate of 1 mL/min 
consisted of a starting solvent system of 5% aqueous acetonitrile and 95% water.  The 
acetonitrile was linearly increased to 20% over three minutes, held four minutes, then increased 
to 100% over two minutes and held thirteen minutes to rinse the column.  Both solvents 
contained 1.0% acetic acid.  A standard was generated in control urine using SF-NAC 
synthesized as previously described (10).   
 
Statistical analysis.  Data were evaluated using the GLIMMIX procedure of SAS Statistical 
software (version 9.1; SAS Institute, Cary, NC).  Levels of SF metabolites in blood and urine 
were tested for interactions of treatment and time.  Differences were separated using the 
SLICEDIFF option.  Values were considered different from controls at p<0.05.     
 
3.3 Results 
Sulforaphane content of hydrolyzed broccoli sprouts and powder.  Upon incubation in 
water at room temperature for 24 h, air-dried broccoli sprouts produced 36.9 ± 1.8 µmol SF per 
gram (approximately 70 µmol / 2 g dose), whereas broccoli powder produced no SF.  Upon 
addition of myrosinase, broccoli powder produced 61.7 ± 2.1 µmol SF per gram (approximately 
120 µmol / 2 g dose).       
 
Hepatic function panel.  The mean measurements for each meal at 24 h post-consumption 
are given in Table 3.1a.  Among meals, no differences were detected for any parameter 
measured.  Most readings were within the normal range; individual panel results outside the 
normal range are shown in Table 3.1b.  All measurements of direct and total bilirubin, alkaline 
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phosphatase and total protein fell within reference ranges.   
 
Plasma total isothiocyanates.  Three hours post-ingestion, broccoli sprout and combination 
meals showed elevated total ITC levels in plasma with mean concentrations of 0.9 ± 0.0 and    
2.1 ± 0.5 µmol/L, respectively (Figure 3.1).  These levels returned to baseline values by 24 h.  
Values for total ITC in plasma following the broccoli powder meal were not different from 
control at any of the time points measured.  When plasma values following the broccoli powder 
meal were compared longitudinally, despite an observed increase between 0 h (0.2 ± 0.0 µmol/L) 
and 24 h (0.5 ± 0.1 µmol/L) post-consumption, the difference was not significant (Figure 3.1).     
  
Sulforaphane-N-acetylcysteine in urine.  The amounts of SF-NAC excreted in the urine 
collected over different time periods within the first 24 hours after ingestion of control and 
treatment meals are shown in Figure 3.2 and Table 3.2.  When individuals ingested broccoli 
sprouts in combination with broccoli powder, they excreted a mean of 93.8 ± 11.8 µmol SF-
NAC over 24 hours post-ingestion; 49% of the dose ingested (Figure 3.2).  After ingestion of 
broccoli sprouts alone, a mean of 52.0 ± 1.4 µmol SF-NAC was excreted; 74% of the ingested 
dose.  However, after ingesting broccoli powder alone, a mean of only 22.6 ± 2.1 µmol SF-NAC 
was excreted, 19% of the dose ingested.   
Urine collection was separated into discrete intervals for evaluation of SF-NAC excretion: urine 
was collected for the first 6 h after meal ingestion (T1), from 6-12 h post ingestion (T2) and from 
12-24 h post ingestion (T3).  Significant differences were seen among dietary groups, with 
substantial levels of SF-NAC excretion detected during T1 for both the combination meal and 
the broccoli sprouts meal (44% and 37% of total SF-NAC excreted within 24 h, respectively), 
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but less than 10% during this first 6 h period from those receiving the broccoli powder meal 
(Table 3.2).  In contrast, only 22% of total from the combination or sprouts meals was excreted 
in the second 12 h period (T3), whereas 39% of SF-NAC excreted following the broccoli powder 
meal was excreted during this later time period.   
The N-acetylcysteine conjugate of erucin, the reduced form of SF, was detected in trace amounts 
in urine from those receiving both the combination and the sprouts meals (data not shown).  No 
erucin metabolite was detected following the powder meal alone.  Treatment of urine samples 
with excess myrosinase did not yield free ITC, indicating that glucoraphanin was not present in 
urine (data not shown).    
 
3.4 Discussion 
In the present study, we measured metabolites in plasma and urine to compare the absorption of 
SF among two broccoli products, alone and in combination; dried broccoli sprouts rich in 
myrosinase and a broccoli powder rich in glucoraphanin, but lacking myrosinase.  Each of four 
subjects ate each meal separated by two or three days washout.  Four subjects is a small study 
population and unfortunately, most clinical studies focusing on glucoraphanin and SF have 
similar small numbers (6-8, 11).  This study was intended to provide data as a pilot study and 
future large scale work is needed to provide greater statistical power and precision.   
The hypothesis, that myrosinase from the sprouts would enhance SF absorption from the broccoli 
powder, was confirmed.  Within whole sprouts, myrosinase is located separately from the 
glucosinolates and hydrolysis of glucoraphanin to SF is therefore not initiated until the onset of 
chewing.   The trend for greater levels of SF-NAC to be excreted early (during T1 and T2) from 
the combination and sprouts meals is consistent with metabolism occurring in the upper 
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gastrointestinal tract in the presence of dietary myrosinase (Table 2).  For the broccoli powder 
meal, hydrolysis may not occur until the meal reaches the colon, the microflora of the gut being 
the source of myrosinase-like thiohydrolase activity (1, 12, 13).  The consequence of late and 
incomplete hydrolysis by colonic microflora is a lower peak plasma level of cancer-preventative 
SF.   
Previous reports providing an ITC extract from hydrolyzed broccoli sprouts (7, 8, 12) showed 
that SF was highly bioavailable, with approximately 80% of the SF dose being recovered as 
metabolites in the urine.  Although we found a very similar recovery from the dried, ground 
sprouts, fresh unhydrolyzed sprouts have been reported to differ in bioavailability depending 
upon the extent of chewing before swallowing (8).  It remains to be determined if fresh sprouts 
can enhance bioavailability of SF from a broccoli preparation lacking myrosinase.  Here we 
found that plasma levels of total ITC were elevated 3 h after consumption of dried, ground 
sprouts.  Broccoli sprouts are an excellent source of SF, as they contain 10-100 fold higher 
concentrations of glucoraphanin compared to mature broccoli.  However, they have a spicy 
“radish” taste which may be un-appetizing to some individuals.  To these individuals, broccoli 
powder may be a tempting alternative, as it lacks flavor and has a high concentration of 
glucoraphanin compared to commercial mature broccoli or sprouts.  The glucoraphanin-rich 
broccoli powder is also heat stable with a prolonged shelf life.  Therefore it can be used in other 
products, such as dietary supplements, many of which are on the market today.  However, since 
it lacks the myrosinase enzyme, SF bioavailability and hence potential for cancer prevention by 
this product is in question.  This study is the first to show the poor yield of SF from such a 
product and the potential for a separate dietary source of myrosinase to improve the SF yield. 
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The broccoli powder, lacking myrosinase, was a poor dietary source of SF compared to broccoli 
sprouts, with only 20% of the dose being recovered as SF-NAC in urine.  This value is 
comparable to reported recovery when cooked sprouts or mature broccoli plants are ingested (6, 
8, 12).  Plasma total ITC was not altered at 3 h in response to the powder meal, but there was a 
trend toward an increase in plasma total ITC at 24 h, suggestive of delayed absorption (9).  This 
delayed hydrolysis is consistent with a lack of myrosinase in the powder resulting in late 
conversion of glucoraphanin to SF by gut microflora.  The possibility was considered that the 
maximum plasma ITC level was delayed rather than absent following ingestion of the powder, 
and thus was not measured in our study.  However, urinary recovery of SF-NAC was low not 
only for the first 6 h, but for the entire 24 h period post consumption, suggesting that any 
possible spike in plasma ITC levels would not be very great relative to that observed for sprouts 
or the combination meal.   
Data from the combination meal were interesting as they identified possible synergy among the 
sprouts and powder at early time point measurements of plasma and urine recovered metabolites.  
This indicates that endogenous myrosinase from the broccoli sprouts had the opportunity to 
hydrolyze glucoraphanin not only from the broccoli sprouts but also from the broccoli powder.  
Whereas our results show that the full 24 h urinary excretion of SF-NAC was additive in the 
combined meal relative to the individual sprouts and broccoli powder meals, plasma total ITC 
for the combined meal at 3 h suggested synergism, in that the 3 h plasma total ITC value for the 
combined meal was significantly greater than the sum of the values obtained for the two 
individual meals at 3 h.  This is further supported by the finding that excretion of SF-NAC 
following the combination meal was earlier than from the broccoli powder alone.  The early 
elevated plasma ITC would translate into an increased potential for cancer-preventative activity. 
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With only 50% of the dose from the combination meal recovered as SF-NAC, it is possible that 
the large amount of unhydrolyzed glucoraphanin from the combination meal may have exceeded 
the capacity of the myrosinase enzyme in the sprouts, leaving myrosinase as the limiting factor in 
this meal.  If this was the case, then increasing the proportion of sprouts to broccoli powder may 
have given even higher SF absorption from the broccoli powder.  Detection of low amounts of 
SF-NAC for a few baseline readings is unaccounted for, but may be due to accidental ingestion 
of glucoraphanin-containing products during the washout period.  No significant carry-over 
effect was detected. 
With regard to safety, the doses provided in this study were similar to or less than that provided 
as whole broccoli in an earlier study (6).  Values of alanine and aspartate aminotransferase below 
normal range (Table 3.1b) do not indicate liver damage or toxicity.  The high value for alanine 
aminotransferase of subject 101 following the broccoli powder meal was also observed following 
the control meal for that individual, suggesting that the elevation was not caused by the broccoli 
meal and that slight elevation of this value may be normal for this individual.  No other listed 
abnormal values were significant.  We conclude that none of the broccoli meals caused any 
hepatotoxicity.   
Taken together, myrosinase from broccoli sprouts allowed early hydrolysis of glucoraphanin 
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3.6 Tables and figures 
 
 





Range Control Powder Sprout Combination 
ALT (U/L) 21-72 38.8 ± 16.2 34.3 ± 14.9 34.3 ± 12.7 34.0 ± 12.6 
AST (U/L) 20-57 28.3 ± 8.7  27.5 ± 9.5 27.8 ± 8.2 28.0 ± 9.0 
Albumin (g/dl) 3.4-4.8 4.5 ± 0.1 4.4 ± 0.1 4.5 ± 0.0 4.5 ± 0.0 
Alk Phos (U/L) 38-126 67.0 ± 6.5 66.8 ± 7.0 67.3 ± 8.5 66.8 ± 6.8 
Bilirubin, D (mg/dl) 0.0-0.3 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
Bilirubin, T (mg/dl) 0.0-1.0 0.6 ± 0.1 0.6 ± 0.0 0.6 ± 0.1 0.5 ± 0.1 
Bilirubin, I (mg/dl) 0.2-1.0 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.0 
T Protein (g/dl) 6.4-8.3 7.4 ± 0.2 7.4 ± 0.2 7.5 ± 0.2 7.5 ± 0.1 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Alk Phos, alkaline 
phosphatase; D, direct; T, total; I, indirect.  Mean ± SEM (n=4) of liver function test values at  











Range Subject Treatment Time  
Observed 
Value 
ALT 21-72 U/L 101 Control 24 h 84 
  101 Powder 24 h 77 
  102 Control 24 h 12 
  102 Powder 0 h 12 
  102 Powder 24 h 14 
  102 Sprout   24 h   12 
  102 Combination 24 h 12 
  104 Control 24 h 19 
  104 Powder 0 h 13 
  104 Powder 24 h 14 
  104 Sprout 24 h 18 
  104 Combination 24 h 18 
AST 20-57 U/L 102 Control 24 h 18 
  102 Powder 0 h 17 
  102 Powder 24 h 20 
  102 Sprout 24 h 18 
  102 Combination 24 h 18 
  103 Powder 24 h 18 
  104 Control 24 h 19 
  104 Powder 0 h 15 
  104 Powder 24 h 16 
  104 Sprout 24 h 17 
  104 Combination 24 h 18 
Bilirubin, indirect 0.2-1.0 mg/dl 104 Powder 0 h 0.2 
Albumin 3.40-4.80 g/dl 101 Control 24 h 4.87 
    102 Powder 24 h 4.82 
ALT, alanine aminotransferase; AST, aspartate aminotransferase.  No abnormal values were 
found at any time point for the following determinations: alkaline phosphatase (38-126 U/L); 
















Figure 3.1.  Mean values of total ITC in plasma at 0, 3, and 24 h after consumption of test meals.  
Data are presented as means of four subjects per group ± SEM. Values indicated by an asterisk 
(*) are significantly different from the control, powder and combination groups, p<0.05.  Values 
indicated by a dagger (†) are significantly different from the control, powder and sprout groups, 






























































Figure 3.2.  Urinary SF-NAC excretion after consumption of control, powder, sprout and 
combination meals.  Baseline (black bars), T1 = 0-6 h (dark grey bars), T2 = 6–12 h (light grey 
bars), T3 = 12-24 h (open bars) urine collection post consumption.  Data are presented as means 





Table 3.2.  Twenty-Four Hour SF-NAC Excretion  












 2.1 ± 2.5
a,1,2
 11.6 ± 2.7
b,3
 8.9 ± 2.4
a,2,3
 
Sprout 0.7 ± 0.5
a,1
 19.3 ± 6.2
b,2,3
 21.4 ± 5.5
b,2
 11.4 ± 1.0
a,3
 
Combination 2.1 ± 2.4
a,1
 41.3 ± 2.4
c,2
 31.6 ± 9.4
c,3
 21.0 ± 4.8
b,4
 
nd, below the limit of detection.  Data are presented as means (µmol) of four subjects per group 
± SEM.  Mean excretion was compared for each time period between control, powder, sprout, 
and combination meals.  Within each column (between-meal values) or each row (within-meal 
values) means that do not share a superscript letter or number, respectively, are significantly 
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4.1 Introduction  
Sulforaphane (SF), found in broccoli as its inactive precursor glucoraphanin (GRP), is 
considered to be responsible for the reduction of cancer risk that is associated with broccoli 
consumption.  Upon crushing or chewing of fresh broccoli or broccoli sprouts, GRP is 
hydrolyzed to SF by the plant thiohydrolase myrosinase.  In instances of myrosinase inactivation, 
such as over-cooking of broccoli, GRP can be hydrolyzed to SF by microflora present in the 
lower gut
 
(1, 2).  However, GRP hydrolysis by microflora of the lower gut is far less efficient 
than hydrolysis by endogenous broccoli myrosinase (3-6). 
Sulforaphane protects against the incidence and progression of cancer via several mechanisms 
including inhibiting phase I cytochrome P450 enzymes, inducing cell cycle arrest and apoptosis, 
reducing inflammation, and perhaps most well-characterized, modulating the nuclear factor-
erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) pathway (7).  In 
the body, SF is metabolized by the mercapturic acid pathway and excreted in urine, mostly as 
sulforaphane-N-acetylcysteine (SF-NAC) (8, 9).  The fate of non-hydrolyzed GRP is less well 
understood.  A recent study reported that low amounts of intact GRP were recovered in the urine 




(9).  Another study reported that low amounts of intact GRP were recovered in the 
urine, but not in the feces of rats that were fed purified GRP
 
(10).           
Several small clinical studies have examined the absorption and excretion of SF in humans.  
When urinary excretion of isothiocyanates (ITC) was measured following ingestion of fully 
cooked or fresh/lightly cooked broccoli, urinary ITC metabolites were approximately three times 
greater from fresh/lightly cooked broccoli than from fully cooked broccoli where myrosinase had 
been heat-inactivated
 
(3, 4).  Similar studies evaluated the appearance of total ITC in urine 
following ingestion of broccoli sprouts that had been either completely hydrolyzed to ITC using 
exogenous myrosinase or contained only GRP where the myrosinase had been destroyed by 
boiling
 
(5, 9).  It was found that ITC excretion was much greater after consumption of the 
preformed ITC compared to the GRP preparations
 
(5, 9).  The results of these studies suggest 
that the conversion of GRP to SF and subsequent ITC bioavailability is dependent on active 
myrosinase. 
In a previous study, a commercially available GRP-powder devoid of myrosinase, typical of 
many dietary GRP supplements on the market, was examined for its potential to deliver bioactive 
SF to human subjects alone or in combination with air-dried broccoli sprout powder, which 
served as an exogenous food source of myrosinase (6).  The results showed that the combination 
improved the absorption of SF, and thus opened the door to the potential for enhanced cancer 
risk reduction not only from GRP supplements, but also from specifically designed foods or food 
combinations
 
(6).      
Due to commercial availability and consumer preferences, intact fresh broccoli sprouts are more 
likely to be ingested by humans than the air-dried broccoli sprout powder used in our previous 
study.  However, fresh broccoli sprouts may present additional variables such as matrix effects or 
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product variability that were not present when examining the air-dried broccoli sprout powder.  
Therefore, the current study examined the same commercially available GRP-powder used in our 
previous study, but here, intact fresh broccoli sprouts were used as the exogenous food source of 
myrosinase.  The present study also expanded the number of blood samples collected to better 
capture the differences in SF appearance in plasma from the test meals.  The study sought to 
determine if the fresh broccoli sprouts would enhance GRP conversion and ITC absorption from 
the GRP-powder.   
 
4.2 Methods  
Fresh broccoli sprouts were donated by Tiny Greens Organic Farm, Urbana, IL, USA.  Broccoli 
powder was a gift from Caudill Seed, Inc., Louisville, KY, USA.   
 
Human subjects study population.  Four healthy men, ages 18-30, were recruited by fliers 
at the University of Illinois at Urbana-Champaign.  Before participating in the study, each 
subject completed baseline questionnaires regarding dietary supplement, tobacco and other drug 
use.  This study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and all procedures involving human subjects were approved by the University of 
Illinois Institutional Review Board.  Written informed consent was obtained from all subjects.  
The study took place January 31-February 25, 2009.   
 
Study design, meal administration and sample collection.  Subjects were randomly 
assigned to a four by four crossover design.  Subjects were given a list of foods known to contain 
glucosinolates and asked to avoid these foods for three days prior to and throughout the entire 
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duration of the study.  Subjects were also requested to avoid the use of dietary supplements and 
to limit alcohol consumption to no more than two alcoholic beverages per day during the study.  
Experimental meals were given each Tuesday for four weeks resulting in a six day washout 
period between meals; the half life for SF is reported as approximately 2 h
 
(11, 12).  The 
morning of each trial, subjects were instructed to ingest a meal according to the crossover design.  
In the case of sprout-containing meals, subjects were also instructed to chew the sprouts 
thoroughly.  Meals included 5 day old intact fresh broccoli sprouts of the calabrese variety 
(approximately 42 g) or GRP-powder (2 g) in an amount that produced 70 or 120 µmol SF, 
respectively, determined by bench hydrolysis.  The combination meal contained both intact fresh 
broccoli sprouts (approximately 42 g) and GRP-powder (2 g).  The GRP-powder was a 
proprietary dry, defatted broccoli seed powder preparation that did not contain myrosinase.  
Experimental meals were accompanied by one cup (53 g) of dry cereal (Go Lean Crunch, Kashi 
Company, La Jolla, CA, USA) and ½ cup (113.5 g) french vanilla fat free yogurt (Stonyfield 
Farm, Londonderry, NH, USA) to serve as a vehicle and control meal.  Thus, the control meal 
included cereal and yogurt only.  Blood (8 ml) was drawn into EDTA vacutainer tubes (BD, 
Franklin Lakes, NJ, USA) immediately before ingestion of each meal (0 h), and at 0.5, 1.0, 1.5, 
3.0 and 24 h following the meal.  Plasma was immediately prepared by centrifugation and stored 
at -80ºC until analyzed.  Urine samples were collected at baseline (0 h), 0-6, 6-12 and 12-24 h 
after meal consumption.  All urine voided during these time intervals was collected.  The 
volumes were recorded and used to calculate total mol of SF-NAC excreted.  Baseline urine 
samples were kept on ice and ascorbic acid (Fisher Scientific, Pittsburgh, PA, USA) was added 
to the urine samples at 1 g/l urine no later than one hour following collection.  All other urine 
samples were collected into 500 ml bottles containing 0.5 g ascorbic acid.  Subjects were 
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instructed to store urine samples in a provided cooler and return them the following morning 
when the 24 h blood samples were collected.  Urine samples were then stored at -80ºC until 
analyzed.    
 
Sulforaphane analysis.  In triplicate, GRP-powder (50 mg) was added to 1.6 ml distilled H2O 
containing 0.8 U white mustard myrosinase (Sigma Chemical, St. Louis, MO, USA), vortexed, 
and left to hydrolyze in the dark for 24 hours.  The mixture was then centrifuged for 5 minutes at 
14,000 x g and filtered through a 0.45 µm nylon filter.  The supernatant was diluted 5-fold with 
distilled H2O and an internal standard of benzyl isothiocyanate (Sigma Chemical, St. Louis, MO, 
USA) was added.  The analysis of the GRP-powder was also conducted in the absence of added 
myrosinase to confirm the necessity of myrosinase in the conversion of GRP to SF.  Fresh 
broccoli sprouts were obtained the day before each trial meal and analyzed for SF production 
upon hydrolysis using a modification of a previously reported method
 
(13).  In triplicate, 0.25 g 
fresh broccoli sprouts were heated at 90ºC for 5 min in a glass vial containing 2 ml dH2O.  
Following heating, samples were cooled on ice, homogenized and 0.5 U white mustard 
myrosinase was added.  Samples were vortexed and left to hydrolyze at room temperature for     
2 h.  The samples were then centrifuged for 5 min at 14,000 x g.  The supernatant filtered 
through a 0.45 µm nylon filter and diluted 4-fold with distilled H2O.  An internal standard of 
benzyl isothiocyanate was added.  Isothiocyanates were extracted into dichloromethane for 
analysis by gas chromatography, as previously described
 
(6).   
 
Plasma total isothiocyanate analysis.  Blood samples were collected in EDTA-coated 




(6).  This method provides a single total measurement for SF, other ITCs 
and metabolites
 
(14, 15).   
 
Urinary sulforaphane-N-acetylcysteine analysis.  Urine samples were analyzed as 
previously described
 
(6).  Briefly, the filtered urine (50 µL) was analyzed by HPLC using a 
Hypersil C18 ODS column (10 m, 250 x 4.6 mm, Phenomenex, Torrance, CA, USA) and 
detected at 254 nm using a Waters HPLC system.  A gradient solvent system with a flow rate of 
1 ml/min consisted of a starting solvent system of 5% aqueous acetonitrile (Fisher Scientific, 
Pittsburgh, PA, USA) and 95% water.  The acetonitrile was increased linearly to 20% over three 
minutes, held four minutes, then increased to 100% over two minutes and held thirteen minutes 
to rinse the column.  Both solvents contained 1.0% acetic acid (Fisher Scientific, Pittsburgh, PA, 
USA).  A standard was generated in control urine using SF-NAC synthesized as previously 
described
 
(16).   
 
Statistical analysis.  Data were evaluated using the GLIMMIX procedure of SAS Statistical 
software (version 9.1; SAS Institute, Cary, NC).  Levels of SF metabolites in urine and blood 
were tested for interactions of treatment and time.  Differences were separated using the 
SLICEDIFF option.  Values were considered different at p<0.05.     
 
4.3 Results 
Sulforaphane content of hydrolyzed broccoli sprouts and GRP-powder.  Upon 
incubation in water at room temperature for 24 h with the addition of 0.8 U myrosinase, GRP-
powder produced 61.7 (SE 2.1) µmol SF/g powder.  No SF was produced in the absence of added 
69 
myrosinase.  Fresh broccoli sprouts produced 1.69 (SE 0.12) µmol SF/g fresh weight.  
 
Plasma total isothiocyanates.  Plasma ITC were elevated compared to baseline at 0.5 h in 
both the sprout and combination meals (Table 4.1).  The combination meal reached peak plasma 
concentration (2.86 (SE 0.33) µmol/l) 1.5 h after ingestion.  The sprout meal peaked at 3 h (1.53 
(SE 0.22) µmol/l), but this value was not different than the value at 1.5 h (1.43 (SE 0.21) µmol/l).  
The GRP-powder meal showed slightly elevated plasma concentration levels 3 h post 
consumption (0.37 (SE 0.25) µmol/l).  However, values following the GRP-powder meal were 
not different from the control meal or baseline measurements at any of the time points measured.  
All values returned to baseline values by 24 h.  
  
Sulforaphane-N-acetylcysteine in urine.  The amount of SF-NAC excreted in the urine 
over 24 h following ingestion of each meal is shown in Figure 4.1.  After ingestion of fresh 
broccoli sprouts in combination with GRP-powder, individuals excreted a mean of               
123.8 (SE 8.8) µmol SF-NAC over 24 hours post-ingestion, 65% of the dose ingested.  After 
ingestion of broccoli sprouts alone, a mean of 42.0 (SE 11.8) µmol SF-NAC was excreted, 60% 
of the ingested dose.  However, after ingesting GRP-powder alone, a mean of only 29.2 (SE 5.0) 
µmol SF-NAC was excreted, 24% of the dose ingested.   
Urine collection was separated into discrete intervals for evaluation of SF-NAC excretion: urine 
was collected for the first 6 h after meal ingestion, from 6-12 h and from 12-24 h post ingestion.  
Significant differences were observed between dietary groups.  Considerable levels of SF-NAC 
were excreted during the first six hours from individuals who received the combination meal or 
the broccoli sprouts meal (61% and 62% of the total SF-NAC that was excreted during the entire 
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24 h urine collection, respectively), but less than 22% of total 24 h SF-NAC was excreted during 
this first 6 h period from those receiving the GRP-powder meal alone.  In contrast, less than 10% 
of total 24 h SF-NAC recovered from the combination or sprouts meals was excreted during the 
12-24 h period, whereas 42% of total 24 h SF-NAC excreted following the GRP-powder meal 
was excreted during this later time period. 
 
4.4 Discussion 
The main findings of this study were that combining fresh broccoli sprouts with the GRP-powder 
(a) increased the appearance of SF metabolites in plasma and urine and (b) removed the delay of 
metabolite appearance observed after the GRP-powder, shifting the absorption/elimination 
pattern to one similar to that seen after the consumption of fresh broccoli sprouts alone.  This is 
the first study to determine if combining two commercially available broccoli products, one 
containing and the other lacking myrosinase, would enhance SF availability from GRP.  This 
research could be extrapolated to hypothesize that combining fresh broccoli sprouts with well-
cooked broccoli, where myrosinase is inactive, would also enhance SF availability.  
Additionally, it could be hypothesized that other sources of myrosinase, such as mustard, 
horseradish, cabbage, Brussels sprouts and watercress, would also enhance the conversion of 
GRP to SF.   
The present study measured urinary SF-NAC excretion and plasma total ITC levels.  The 
measurement of SF metabolites after consumption of broccoli, broccoli sprouts, and other 
broccoli related preparations has been a useful tool for assessing human exposure to SF, a 
compound associated with reduced risk for cancer
 
(1, 3-6, 9, 17, 18).  Sulforaphane metabolites 
in plasma reflect the amount of SF that tissues are being exposed to and are therefore important 
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biomarkers of exposure to this cancer preventative agent.  Sulforaphane metabolites in urine 
reflect the absorption, metabolism and excretion of an ingested dose
 
(5).  The major metabolite 
of SF appearing in urine, SF-NAC, is often used as a marker of bioavailability, although it is not 
the only metabolite present in urine
 
(8, 9).   
Only 24% of the GRP dose from the GRP-powder was recovered as SF-NAC in the urine, 
making it a poor source of dietary SF compared to fresh broccoli sprouts.  This value is 
comparable to the reported recovery following ingestion of well-cooked sprouts or well-cooked 
mature broccoli that both also lacked myrosinase
 
(3, 5, 18).  Urinary values of SF-NAC after the 
GRP-powder meal displayed a non-significant trend of increasing excretion over 24 hours, 
suggestive of delayed absorption.  The delayed absorption and low SF recovery was likely due to 
the lack of myrosinase in the powder and the resulting hydrolysis of GRP occurring by 
microflora after transit of GRP to the lower gut
 
(1, 2, 18, 19).  Plasma total ITC was not altered 
in response to the GRP-powder, but there was a slight non-significant elevation at 3 h, also 
suggestive of delayed ITC absorption with low availability.  It could be questioned if the 
maximum plasma ITC level was further delayed rather than absent following ingestion of the 
GRP-powder, and thus was not measured in this study.  Indeed, a slight, but non-significant peak 
6 h post-consumption was observed in a study of well-cooked broccoli
 
(3).  However, urinary 
recovery of SF-NAC was low not only for the first 6 h of the present study, but for the entire    
24 h period following consumption of the GRP-powder meal, confirming the absence of any 
significant elevation in plasma ITC levels.  The low levels of SF metabolites detected in plasma 
and urine after consumption of the GRP-powder may indicate lower anti-cancer potential for this 
product and other similar dietary supplements.  For instance, it was reported that similar GRP 
products lacking myrosinase induced detoxification enzymes in the colon, but not liver of rats, 
72 




Interestingly, data from the combination meal identified possible synergy among the fresh 
sprouts and GRP-powder at early time points for SF and metabolites appearance in plasma and 
urine.  This indicates that GRP, not only from the broccoli sprouts, but also from the GRP-
powder, was hydrolyzed by endogenous myrosinase from the broccoli sprouts.  Additionally, 
excretion of SF-NAC following the combination meal was earlier than from the GRP-powder 
alone and more similar to the excretion pattern following consumption of broccoli sprouts alone, 
indicating that the fresh sprouts not only supported hydrolysis of the GRP-powder, but also 
caused it to occur earlier, resulting in earlier and more complete SF absorption.  The trend for 
greater levels of SF-NAC to be excreted early (during the first 12 h following meal consumption) 
from the combination and sprouts meals is consistent with metabolism occurring in the upper 
gastrointestinal tract in the presence of dietary myrosinase.  A similar trend was observed in 
plasma where in both sprout and combination meals, plasma ITC levels were elevated by 0.5 h, 
and to a much higher level in the combination meal.  Higher levels of SF metabolites in plasma 
and urine may indicate greater reduction of cancer risk from consumption of this food 
combination.   
It has been reported that approximately 74% of dietary SF is absorbed in the jejunum (21).  
Elevation of plasma ITC levels at 0.5 h post-consumption of the sprout and combination meals 
may indicate that a portion of SF was absorbed at a point in the digestive tract as early as the 
stomach and/or duodenum.  Considering the small volume of food and low amount of fat 
consumed in these trial meals, the observation that the highest levels of plasma ITC occurred 
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between 1.5-3 h post-consumption was consistent with the expected majority of SF absorption 
occurring in the jejunum/upper intestine.         
Recovery of preformed ITC or ground, air-dried broccoli sprouts was reported to be between 75-
90% of ingested doses
 
(5, 6, 22).  This recovery decreased when a plant matrix was introduced, 
as is evidenced by several published papers, as well as the present paper where intact, but 
thoroughly chewed fresh sprouts resulted in a 60% recovery of the dose
 
(3, 5, 22).  Interestingly 
though, comparing an equimolar dose of SF from fresh sprouts (used here) to air-dried sprouts
 
(6) when combined with the GRP-powder, an improved 24 h urinary recovery (65% versus 50% 
of the ingested dose, respectively), and an elevated peak plasma ITC level (Cmax 2.9 versus 
2.1µmol total ITC/l, respectively) was observed in the combination using fresh intact broccoli 
sprouts.  Based on this evidence, we conclude that fresh broccoli sprouts aided the conversion of 
GRP to SF from GRP-powder to a greater extent than air-dried broccoli sprouts.  More research 
with larger study populations is needed.  
One limitation of the present study is its small sample size.  However, most human studies 
focusing on the bioavailability of SF use similar small population sizes
 
(3, 5, 6, 11).  The intent 
of this study was to provide direction as a pilot study.  Future large scale work is needed.  
In conclusion, the GRP-powder that lacked myrosinase was a poor dietary source of SF 
compared to broccoli sprouts.  Fresh intact broccoli sprouts were able to synergistically enhance 
the hydrolysis of GRP from the GRP-powder, perhaps more efficiently than ground, air-dried 
broccoli sprouts.  Because efficacy is related to plasma levels, the elevation seen in plasma levels 
likely translates to greater potential for cancer risk reduction.  These findings provide important 
insights into the protective health benefit of broccoli products and preparations and can be used 
to develop foods with enhanced anti-cancer properties.  
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4.6 Tables and figures 
  
 
Table 4.1.  Total ITC in Plasma Following Test Meal Consumption  
  0 h  0.5 h  1 h  1.5 h  3 h  24 h 
(µmol total ITC/l)  Mean SE  Mean SE  Mean SE  Mean SE  Mean SE  Mean SE 
control  0.22
a,1
 0.09    0.18
a,b,1
 0.11  0.24
a,1
 0.06  0.16
a,1
 0.13  0.05
a,1





 0.07  0.11
a,1
 0.07  0.07
a,1
 0.03  0.12
a,1
 0.11  0.37
a,1
 0.25  0.16
a,1
 0.10 
fresh sprout  0.13
a,1
 0.12  0.46
b,1
 0.11  0.97
b,2
 0.15  1.43
b,3
 0.21  1.53
b,3





 0.07  1.26
c,2
 0.22  2.14
c,3
 0.15  2.86
c,4
 0.33  2.57
c,4




Data values are µmol total ITC/l, n=4 subjects per group.  Within each column (between-meal values) or each row (within-meal 
values) means that do not share a superscript letter or number, respectively, are significantly different, p<0.05. 
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Figure 4.1.  Urinary SF-NAC (sulforaphane-N-acetylcysteine) excretion after consumption of 
four different meals: control, GRP-powder, fresh broccoli sprout and combination.  Baseline 
(black bars), 0-6 h (dark grey bars), 6–12 h (light grey bars), 12-24 h (open bars) urine collection 
post consumption.  Data are presented as means of four subjects per group with standard errors 
represented by vertical bars.  Between-meal values that do not share a letter or within-meal 










































Sulforaphane Decreases DNA Methylation and Increases Gene Expression of P21 
in Human Colorectal Carcinoma Cells 
 
5.1 Introduction 
Sulforaphane (SF) is an isothiocyanate derived from the hydrolysis of glucoraphanin, a natural 
constituent of broccoli, and is considered to be responsible for the chemoprotective benefit 
associated with broccoli consumption.  Sulforphane is known to activate the nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2)/Antioxidant Response Element (ARE) pathway causing 
upregulation of detoxification enzymes that protect against the incidence and progression of 
cancer (1-3).  The Nrf2/ARE pathway is the best-characterized mechanism by which SF exerts 
its anti-cancer effect (4).  However, additional anti-carcinogenic pathways involving epigenetic 
gene regulation are being explored.   
Histone acetyltransferases are enzymes that transfer acetyl groups to histones, whereas histone 
deacetylases (HDAC) remove acetyl groups from histones (5).  The balance between histone 
acetyltransferase and HDAC enzymes determines the acetylation level of histones.  Greater 
acetylation of histones is generally associated with transcriptional activation of a gene (5).  By 
decreasing the acetylation status of nucleosomes, HDAC can limit the access of transcriptional 
machinery to DNA (6).  Thus, inhibition of HDAC activity is associated with gene activation (6, 
7).  Trichostatin A (TSA) is a classic HDAC inhibitor and is often used as a positive control in 
studies evaluating inhibition of HDAC activity (7-9).   
DNA methylation is catalyzed by DNA methyltransferase enzymes (DNMT).  Hypermethylation 
at the promoter regions of several tumor suppressor genes is associated with gene silencing in 
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cancer (6).  Thus, inhibition of DNMT activity is a promising method for reducing promoter 
hypermethylation and restoring expression of tumor suppressor genes in cancer.  The nucleoside 
analog 5-azacytidine (AZA) been shown to reduce DNA methylation by inhibiting DNMT and is 
used clinically for this purpose (5, 10, 11).  5-azacytidine is also frequently used as a positive 
control in studies evaluating DNA demethylation.   
Histone post-translational modifications, including histone acetylation level, are linked to DNA 
methylation (12-14).  Histone modifying enzymes can recruit the DNA methylation machinery 
and conversely, methylated DNA can recruit histone-modifying complexes, including HDAC 
(12, 13).  Interestingly, the HDAC inhibitor valproic acid stimulates gene expression by both 
preventing histone deacetylation and concurrently stimulating DNA demethylation (15, 16).  
Therefore, HDACs and DNA methylation can work together to effectively regulate gene 
expression. 
Many cancers, including colorectal cancer (CRC), have an epigenetic basis involving 
dysregulation of histone modifications and DNA methylation with an associated aberrant 
transcriptional silencing of gene expression (6, 17-19).  Furthermore, both HDAC and DNMT 
enzymes are typically overexpressed in CRC, contributing to the state of gene silencing (20-22).  
Epigenetic changes, rather than genetic mutations, are responsible for as many as 50% of the 
tumor suppressor genes silenced in cancer, and aberrant DNA methylation is a hallmark of 
numerous cancers (19, 23, 24).  Sulforaphane is an inhibitor of class I HDAC, ubiquitously 
expressed nuclear HDAC enzymes involved in gene silencing, suggesting it may affect 
epigenetic gene regulation (8, 22).  Sulforaphane treatment was also recently reported to down 
regulate DNMT enzymes (25).  Thus, the chemoprotective effect of dietary SF may be due to a 
role in normalizing epigenetic regulation of gene expression.  
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A few dietary anticarcinogens, including epigallocatechin-3-gallate, lycopene and genistein, have 
been shown to increase gene expression by inducing DNA demethylation of aberrantly 
hypermethylated gene promoters (26-28).   Sulforaphane may similarly decrease DNA 
methylation levels.  As stated previously, SF treatment was recently reported to down regulate 
DNMT1 and DNMT3a resulting in decreased DNA methylation in breast cancer cells (25).  
However, the gene evaluated in this study was telomerase reverse transcriptase, a gene that is 
activated by methylation.  Therefore, demethylation correlated with repression of gene 
expression (25).  In the present study, SF was tested for the ability to stimulate DNA 
demethylation and upregulate gene expression of cyclin-dependent kinase inhibitor 1A (P21), 
BCL2-associated X protein (BAX), cyclin-dependent kinase inhibitor 2A (P16), O-6-
methylguanine-DNA methyltransferase (MGMT) and mutL homolog 1 (MLH1) using human 
CRC cells.  P21, BAX, P16 and MGMT were selected based on their reported upreguation by SF 
as well as their status as tumor suppressor genes (22, 29, 30).  MLH1 was selected because this 
tumor suppressor gene is commonly hypermethylated in CRC (31, 32).   
 
5.2 Methods  
Cell culture.  HCT 116 human colorectal carcinoma cells (American Type Culture Collection, 
Manassas, VA) were maintained with McCoy’s 5A medium supplemented with 10% fetal bovine 
serum.  Cells were cultured at 37ºC in a humidified atmosphere of 95% air and 5% carbon 
dioxide.  A preliminary study was carried out in duplicate to determine if SF caused loss of cell 
growth and/or cell death at 5.0 µM SF.  Cells were plated at 5 x 10
4 
cells/well in 6 well plates 
and allowed to attach for 24 h.  On days 1, 3, 5, and 7 medium was removed and replaced with 
fresh medium containing 5 µM SF (LKT Laboratories, St. Paul, MN) or no treatment (control).  
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The treatment and control contained 0.1% DMSO.  Trypsinization followed by trypan blue 
staining and cell counting was used on days 1, 3, 5, 7 and 9 to carry out a growth curve assay and 
evaluate cytotoxicity.  Adherent cells that did not accumulate trypan blue were counted as live.  
Adherent cells that accumulated trypan blue and all floating cells were counted as dead.   
Next, HCT 116 cells were again plated at 5 x 10
4 
cells/well in 6 well plates and allowed to attach 
for 24 h.  Medium was removed and replaced with fresh medium containing 5 µM SF or no 
treatment (control) on days 1, 3 and 5.  The treatment and control contained 0.1% DMSO.  On 
day 7, cells were harvested by trypsinization.  DNA or RNA was isolated for use in methylation-
specific PCR and quantitative real-time RT-PCR as described below.  Trypan blue staining and 
cell counting were used to measure cell growth and cytotoxicity in triplicate on day 7.  Adherent 
cells that did not accumulate trypan blue were counted as live.  Floating cells were not assessed. 
  
Methylation-specific PCR.  DNA was isolated using the Qiagen DNeasy Blood and Tissue 
Kit and quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, 
DE).  DNA was treated with sodium bisulfite using the Zymo Research EZ DNA Methylation-
Gold Kit.  Gene promoter sequences for primer design were obtained from ensembl.org.  
Primers, listed in Table 5.1, were designed using MethPrimer software (33).  PCR was 
performed using the following program: 15 min at 95˚ C, followed by 35 cycles of 30 sec at    
95˚ C, 30 sec at the annealing temperature listed in Table 5.1, 30 sec at 72˚ C, and final extension 
at 72˚ C for 5 min.  PCR products were resolved on a 2% agarose gel, stained with ethidium 
bromide and quantified by densitometry (ChemiImager 4400, Alpha Innotech, San Leandro, 
CA).   
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Quantitative real-time RT-PCR.  RNA was isolated using the Qiagen RNeasy Mini Kit with 
RNase-free DNase; a denaturing agarose gel confirmed RNA integrity.  cDNA was generated 
using the Invitrogen SuperScript VILO cDNA synthesis kit.  Primers were designed using Primer 
Express software (version 2; Applied Biosystems, Carlsbad, CA) according to the manufacturer 
and are shown in Table 5.2.  Real-time PCR was performed using Power SYBR Green PCR 
Master Mix (Applied Biosystems) with a TaqMan ABI 7900HT Fast Real-Time PCR System 
(Applied Biosystems) according to the manufacturer protocol.  Data were analyzed using 
Sequence Detection System software version 2.4 (Applied Biosystems) and normalized to beta-
actin.  Results are expressed as fold change over control using the comparative CT method. 
 
HDAC activity assay.  HCT 116 human colorectal carcinoma cells plated at a density of        
2 x 10
5
 cells/100 mm tissue culture dish.  Cells were maintained and treated as described above 
except that treatments included 1.0, 2.5 or 5 µM SF or no treatment (control).  The treatments 
and control contained 0.1% DMSO.  On day 7, cells were harvested by trypsinization and 
nuclear extracts were prepared using the EpiQuick Nuclear Extraction Kit (Epigentek, Brooklyn, 
NY).  Nuclear extracts (20 µg) from cells were assayed for HDAC activity using a colorimetric 
HDAC activity assay kit (Actif Motif, Carlsbad, CA).  Trichostatin A was added directly to 
nuclear extract from control cells to serve as a positive control. 
 
DNMT activity assay.  Cells were maintained and treated as described for the HDAC activity 
assay.  Nuclear extracts (5 µg) were assayed for DNMT activity using the colorimetric EpiQuick 
DNMT Activity/Inhibition Assay Ultra Kit (Epigentek, Brooklyn, NY).  Cells treated with 1.0 or 
5.0 µM AZA served as a positive control.  Additionally, nuclear extract from control cells was 
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directly treated with a final concentration of 5.0 µM SF to determine whether SF was a direct 
inhibitor of DNMT.   
 
Statistical analysis.  Data were evaluated by one-way analysis of variance (ANOVA) using 
SAS Statistical software (version 9.1; SAS Institute, Cary, NC).  Where a significant effect was 
found (F-ratio, P<0.05), Fisher’s LSD post-hoc test was used to determine significant differences 
between means.  Data are presented as mean ± SD. 
 
5.3 Results 
Cell growth and cytotoxicity assays.  HCT 116 cells were grown with and without 5.0 µM 
SF and harvested on day 7.  As predicted from preliminary studies (Figures 5.1a and 5.1b), 
triplicate studies of adherent cells showed that growth was inhibited by approximately 53% in 
the SF treated cells compared to untreated control cells (Figure 5.1c).  Cell survival was            
99 ± 0.01% in SF treated cells which was indistinguishable from the untreated controls            
(99 ± 0.01% survival) indicating that 5.0 µM SF treatment for 7 days was not cytotoxic (data not 
shown).       
 
Methylation-specific PCR.  Quantitative methylation-specific PCR (MSP) analysis of DNA 
from cells treated with 5.0 µM SF for 7 days showed a 14% reduction of promoter DNA 
methylation for the P21 tumor suppressor gene and a non-significant 11% reduction of DNA 
methylation at the promoter of BAX (Figure 5.2).  No significant change in DNA methylation 
status was observed at the promoters of MGMT, which remained 100% methylated for control 
and SF treatments (data not shown), or P16, which showed 52.3 ± 4.9 and 49.7 ± 3.1% 
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methylation for control and SF treatments, respectively (Figure 5.2).  The promoter of MLH1 
was 0% methylated in control cells leaving no opportunity for SF to result in demethylation of 
the promoter of this gene (data not shown).  As expected, cells treated with 5.0 µM SF also 
revealed 0% methylation at the MLH1 promoter (data not shown).       
 
Quantitative real-time RT-PCR.  The P21 and BAX mRNA showed a 1.92 ± 0.32 and    
1.64 ± 0.09 fold increase over mRNA from untreated control HCT 116 cells in response to       
5.0 µM SF treatment, indicating an increase in gene expression concordant with DNA 
demethylation (Figure 5.3).   
 
HDAC activity assay.  HDAC activity was not changed in response to any concentration of 
SF tested (Figure 5.4).  However, HDAC activity was decreased in the TSA treated nuclear 
extracts from control cells that were included as a positive control, indicating that the assay was 
functioning correctly.     
 
DNMT activity assay.  DNMT activity following 7 day treatment with 1.0, 2.5 or 5.0 µM SF 
was 111.9 ± 7.3, 81.5 ± 11.4 and 70.2 ± 9.8% respectively, of untreated controls (Figure 5.5).  
However, only the 5.0 µM SF treatment caused a significant decrease in DNMT activity.  Both 
2.5 and 5.0 µM SF resulted in significantly lower DNMT activity than 1.0 µM SF, but were not 
different from each other (Figure 5.5).  Although 1.0 µM AZA had no effect on DNMT activity, 
5.0 µM AZA decreased DNMT activity to 58.0 ± 10.0% of untreated control (Figure 5.5).  A 
final concentration of 5.0 µM SF added directly to nuclear extract of untreated control cells did 
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not alter DNMT activity, indicating that SF does not inhibit DNMT through direct inhibition 
(Figure 5.5).     
       
5.4 Discussion 
According to the National Cancer Institute, CRC is the third most common cancer and third 
leading cause of cancer-related deaths in the United States with 142,570 new cases and      
51,370 deaths estimated for 2010.  If cancer prevention is to be an effective strategy for 
decreasing cancer deaths, then it is necessary to identify and inhibit the early changes of the 
cancer process.  Epigenetic changes often occur during the earliest stages of CRC development 
providing an opportunity for epigenetically targeted compounds to impact cancer prevention (23, 
34).  Because of direct contact, the digestive tract may be exposed to higher levels of dietary 
bioactive compounds compared to other organs and epidemiological data indicate that cancers of 
the digestive tract are particularly responsive to dietary components (35).  Additionally, higher 
consumption of broccoli and other related vegetables correlate with reduced risk of CRC (36).  In 
one study, the diets of 586 adult male patients with colon or rectal cancer were compared to the 
diets of 1411 control adult males who did not have these cancers (36).  An increase in risk of 
colon and rectal cancer was found with lower frequency of vegetable intake; specifically 
cabbage, Brussels sprouts and broccoli (36).  Therefore, it is interesting to determine if dietary 
factors, such as SF, impact epigenetic targets to provide a unique opportunity for CRC 
prevention and/or reduced tumor progression. 
Sulforaphane is a natural agent present in broccoli known to inhibit HDAC activity and is a 
prime candidate for mediating the chemoprotective effects of broccoli consumption towards 
CRC.  Levels of SF metabolites in plasma can reach 7 M, but more commonly reach Cmax at    
86 
2-3 M (37-41).  To test the potential efficacy of dietary SF as an anti-cancer treatment, 
concentrations in the range of 1.0-5.0 M SF were chosen for this study.  Treatment of HCT 116 
cells with 5.0 M SF over 7 days resulted in cell survival indistinguishable from the untreated 
controls (99 ± 0.01% survival in both groups) indicating no cytotoxic effects of the SF.  
However, 7 days of SF treatment inhibited cell growth by approximately 53% compared to 
control untreated cells.  Thus, the 5 M SF obtainable in circulating plasma through broccoli 
consumption is both non-toxic and growth-suppressive on CRC cells. 
Many CRCs have epigenetic alterations, including aberrant DNA methylation patterns, 
associated with their transformation.  To determine if SF may be exerting its anti-cancer effects 
through targeting epigenetic mechanisms, DNA methylation analysis was performed on several 
candidate tumor suppressor genes (P21, BAX, P16, MGMT) known to be upregulated by SF (22, 
29, 30).  DNA methylation was also assessed at the promoter of MLH1 because this tumor 
suppressor gene is commonly hypermethylated in CRC (31, 32).  Quantitative methylation-
specific PCR analysis showed a gene-specific effect in which SF treatment resulted in a 14% 
reduction of promoter DNA methylation for the P21 tumor suppressor gene and a non-significant 
effect at the promoter of BAX.  No change in DNA methylation status was observed at the 
promoters of MGMT, P16 or MLH1.  The DNA demethylation of P21 is particularly interesting 
because the P21 gene encodes a cyclin-depedent kinase inhibitor that is involved in regulation of 
the cell cycle, specifically blocking the progression from G1 to S phase.  Sulforaphane has been 
reported to inhibit G1 to S phase transition, although the mechanism has not been established 
(42-44).  Therefore, P21 demethylation may be involved in the observed growth inhibition by 
SF. 
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If it has biological significance, the DNA methylation status of promoter CpG islands can be 
expected to correlate with gene expression.  Therefore, quantitative real-time RT-PCR (qRT-
PCR) was used to assay the P21 and BAX mRNA expression levels in response to SF treatment.  
The P21 and BAX mRNA both showed an increase over untreated control in response to SF 
treatment, indicating an increase in gene expression concordant with DNA demethylation.  
Previously, treatment of MCF-7, MDA-MB-231 and MCF10A breast cancer cells with 5 µM SF 
was shown to decrease promoter DNA methylation of telomerase reverse transcriptase, although 
the effect was more robust at 10 µM SF (25).  Therefore, the results reported here might be more 
robust if examined at higher SF concentrations, but it must be kept in mind that such levels 
would no longer carry relevance to dietary SF from broccoli.  At a physiologically relevant level 
for dietary protection, we demonstrated that SF was an activator of P21 and BAX mRNA 
expression in addition to being efficient at stimulating DNA demethylation. 
Histone modifying machinery as well as DNA methylation machinery are involved in regulating 
the epigenetic landscape of cells.  The epigenetic machinery responsible for histone 
deacetylation and DNA methylation can interact to effectively silence genes (12, 13).  HDAC 
inhibition by SF was previously reported over a range of 3.0-15.0 µM SF (8).  Therefore, HDAC 
and DNMT activity were assayed in order to elucidate a potential mechanism for the observed 
decrease in promoter DNA demethylation of SF treated cells.  Specifically, we sought to 
determine whether the decrease in DNA methylation was due to the coupled action of HDAC 
and DNMT inhibition, or if the observed promoter DNA demethylation was independent of 
HDAC inhibition.  In our study, no effect on HDAC was observed following any concentration 
of SF treatment, despite SF being a known competitive inhibitor of HDAC.  However, it has 
been shown that SF must be present to maintain HDAC inhibition (21).  In the present study, the 
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final SF treatment was administered to confluent cells 48 h before harvest.  Unpublished data 
from our lab indicate that the concentration of SF in medium devoid of cells after 48 h 
incubation at 37ºC is negligible.  Therefore, it is not surprising that a decrease in HDAC activity 
was not observed, as it is likely that SF had been depleted.  Cells treated with increasing 
concentrations of SF showed a pattern of decreased DNMT activity and reached significance at 
5.0 M SF.  However, nuclear extract from untreated control cells treated acutely with 5.0 M 
SF did not show decreased DNMT activity, suggesting that the inhibition of DNMT activity by 
SF is not acting directly at the enzyme.  Therefore, the underlying mechanism for the decrease in 
promoter DNA demethylation at 5.0 M SF appears to involve indirect inhibition of DNMT 
activity.  In support of this hypothesis, Meeran et al. observed decreased DNMT protein 
expression following SF treatment in breast cancer cells (25).   
DNA methylation is not the only SF-affected pathway relating to cancer.  Triggering the 
Nrf2/ARE pathway is the mechanism most commonly attributed with the reduction of cancer 
observed after exposure to SF.  However, none of the genes evaluated in the present study were 
found to be regulated by Nrf2/ARE and P21 has specifically been shown to lack an ARE (8, 45).  
Therefore, it is likely that upregulation of P21 by SF occurs through a Nrf2-independent 
mechanism, consistent with a biological role for SF affecting DNA demethylation.  In addition, 
only P21 (and BAX to a lesser extent) was associated with loss of methylation by SF, indicating 
selectivity of the impact of SF on DNA demethylation.  Demethylation of specific gene targets is 
important since global genome demethylation has been associated with undesirable effects (46).  
These data suggest that administration of SF, either through dietary broccoli or through other 
means, can affect the epigenome beneficially, with the potential to slow or prevent cancers, 
particularly those of the colon. 
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5.6 Tables and figures 
 
 




reaction Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temperature (˚C) 
P21 M ATGTGTTTAGCGTATTAACGTAGGC GACTCCACAAAAAACTAACTTCGAC 50 
 U TGTGTTTAGTGTATTAATGTAGGTGA AACTCCACAAAAAACTAACTTCAAC 50 
BAX M GTTGGGGAGAGTTTAAATTTTGTTC GCTAAACGTACGTCCTCCACGTA 50 
 U GTTGGGGAGAGTTTAAATTTTGTTT CCCACTAAACATACATCCTTCACATA 50 
P16 M AGTAGTTGGGATTATAGGTATGCGT ATTCTAAAAAACCGAAACAAACG 48 
 U GAGTAGTTGGGATTATAGGTATGTGT ATTCTAAAAAACCAAAACAAACAAA 48 
MGMT M GAGAGATTCGCGTTTCGGGTTTAG AACGACGCCTTCCCAACTTC 53 
 U TTGGGTATGTGGTAGGTTGTTTGT ACACCAACACACCAACCCTA 53 
MLH1 M AGTGAAGGAGGTTACGGGTAAGTC TATCGCCGCCTCATCGTAACT 53 
 U AGAGGTGGTAGAGTTTGAGGTTTG CACCACCTCATCATAACTACCCA 53 







Table 5.2.  Primer Sequences for Quantitative Real-Time RT-PCR 
 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
P21 GAGACTCTCAGGGTCGAAAACG TGGTAGAAATCTGTCATGCTGGTC 
BAX TGTCGCCCTTTTCTACTTTGC GTGCACAGGGCCTTGAGC 
ß-actin CTGGCACCCAGCACAATG CTTGCGCTCAGGAGGAGC 
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Figure 5.1.  The effect of SF treatment on cell growth and cytotoxicity.  a) Growth curve and b) 
cytotoxicity was determined after treatment of HCT 116 cells with 5.0 M SF on experimental 
days 1, 3, 5, 7 and 9.  At each time point, cells were harvested, stained with trypan blue and 
counted.  Adherent cells that did not accumulate trypan blue were counted as live.  Adherent 
cells that accumulated trypan blue and all floating cells were counted as dead.  Data represent the 
mean of duplicate samples.  c) In a separate experiment, HCT 116 cells were treated with 5.0 M 
SF for 6 days; on experimental day 7, cells were harvested, stained with trypan blue and counted.  
Adherent cells that did not accumulate trypan blue were counted as live.  Floating cells were not 








Figure 5.2.  The effect of SF treatment on promoter DNA methylation.  HCT 116 cells were 
treated with 5.0 M SF or no treatment (control) every 48 h for 6 days and harvested on day 7.  
The effect of 5.0 M SF on the DNA methylation status of P21 (light grey bars), BAX (open 
bars), and P16 (dark grey bars) was assayed by MSP and quantified by densitometry, as 
described in methods.  Data represent mean ± SD of three independent experiments.  One 
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Figure 5.3.  The effect of SF treatment on P21 (a) and BAX (b) mRNA expression.  HCT 116 
cells were treated with 5.0 M SF or no treatment (control) every 48 h for 6 days and harvested 
on day 7.  The effect of 5.0 M SF treatment on P21 and BAX mRNA expression level was 
assayed by qRT-PCR, normalized to -actin, and expressed as fold change over untreated control 
using the comparative CT method.  Data are presented as mean ± SD of three independent 






Figure 5.4.  The effect of SF treatment on HDAC activity.  HCT 116 cells were treated with 1.0, 
2.5 or 5.0 M SF or no treatment (control) every 48 h for 6 days and harvested on day 7.  The 
effect of SF treatment on HDAC activity was assessed.  A final concentration of 1.0 M 
Trichostatin A added directly to nuclear extract of control cells during the HDAC activity assay 
served as a positive control for the assay and inhibited HDAC activity to 74.2 ±10.2 percent of 
untreated control.  Data are expressed as percent activity of untreated control and presented as 
mean ± SD of three independent cultures, each measured in duplicate.  At p<0.05 compared to 








Figure 5.5.  The effect of SF on DNMT activity.  HCT 116 cells were treated with 1.0, 2.5 or   
5.0 M SF; 1.0 or 5.0 M 5-azacytidine (AZA) (positive controls); or no treatment (control) 
every 48 h for 6 days and harvested on day 7.  The effect of these treatments on DNMT activity 
was assessed.  Additionally, a final concentration of 5.0 M SF was introduced directly to 
nuclear extract of control cells during the DNMT activity assay (control NE + SF 5.0 M).  Data 
are expressed as percent activity of untreated control and presented as mean ± SD of three 
independent cultures each measured in duplicate.  P<0.05 compared to untreated control (*),    




Conclusion and Future Directions 
 
6.1 Conclusion 
The overall conclusion of this body of work is that combined consumption of glucoraphanin and 
a source of myrosinase could be an effective way of attaining plasma concentrations of SF 
through the diet that are reflective of concentrations correlated with an epigenetic impact in a cell 
culture model.  Specifically, consumption of glucoraphanin with broccoli sprouts as the source of 
myrosinase resulted in enhanced exposure to SF indicated by elevated concentrations of total 
ITC in plasma and greater recovery of SF-NAC in urine.  Plasma total ITC levels reached      
2.86 ± 0.33 µM at 1.5 h post-ingestion of the fresh broccoli sprout plus glucoraphanin powder 
combination meal.  A concentration of SF similar to that attained in human plasma after 
consumption of the combination meal was associated with markers of epigenetic activation of 
tumor suppressor genes in a cell culture model of CRC.  In particular, 5 µM SF for 7 days 
decreased DNA methylation at the promoter of P21.  The demethylation correlated with an 
increase in P21 mRNA expression and an inhibition of DNMT activity.  The activity of HDAC 
was not affected by this study.  Therefore, a physiologically relevant concentration of SF resulted 
in decreased promoter DNA methylation through a mechanism that likely involved decreased 
DNMT activity.         
A few studies have recently been published that extend our findings concerning the 
bioavailability of glucoraphanin supplements in humans.  In one such study,  ingestion of        
221 µmol glucosinolates from fresh broccoli sprouts with active myrosinase resulted in an 
approximately eight fold greater peak plasma total ITC concentration and more than a four fold 
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greater recovery of urinary SF and metabolites compared to ingestion of 161 µmol glucosinolates 
from a myrosinase-lacking broccoli supplement (1).  This study, like ours, also demonstrated a 
delay in peak plasma total ITC and urinary recovery of SF and metabolites following the 
supplement alone in comparison to the fresh broccoli sprouts alone (1).  Additionally, they 
showed that SF and erucin, the reduced form of SF, were able to be interconverted in humans 
(1), confirming studies from rats (2).  Finally, when fed equivalent doses of glucosinolates from 
fresh broccoli sprouts or a broccoli supplement, these authors showed that excretion of urinary 
SF and erucin metabolites occurred earlier and to a greater extent after consumption of the 
broccoli sprouts (3).  Inhibition of HDAC activity in mononuclear cells from blood samples of 
these subjects was decreased only by the broccoli sprout meal (3).  The peak plasma 
concentration of total ITC that correlated with inhibition of HDAC activity was not reported (3).  
HDAC inhibition following human consumption of broccoli sprouts has been reported 
previously (4).  However, the concentration of SF metabolites in plasma that correlated with 
HDAC inhibition was not measured (4).  Therefore, the concentration of SF metabolites in 
plasma that correlates with a decrease in HDAC activity in humans remains to be established.  A 
second group also extended our studies, reporting that ingestion of 800 µmol glucoraphanin 
resulted in urinary recovery of only approximately 22 µmol SF and metabolites, whereas        
150 µmol preformed SF resulted in approximately 84 µmol recovered (5).  This translates to an 
almost four fold higher recovery of urinary SF metabolites from a 5.3 fold lower dose. 
Together, these studies confirm the low bioavailability from glucoraphanin supplements reported 
in our clinical studies which further demonstrates the importance of improving the bioavailability 
of these products.  As we have shown in chapters 3 and 4, one way to accomplish this is to 
include a source of myrosinase with the supplement in order to increase the hydrolysis and 
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subsequent biological exposure to the anti-cancer agent SF.  It is known that SF is an inhibitor of 
HDAC activity in human mononuclear cells from blood (3, 4).  While this provides evidence that 
dietary SF has epigenetic bioactivity in humans, the effective plasma concentration to obtain this 
result is not established.  Future work is needed to determine whether dietary SF can also affect 
the activity of DNMT and DNA promoter methylation in animal and human models.  
 
6.2 Future directions 
Future work for clinical studies 
Most importantly, I think a clinical study with a larger subject population should be conducted in 
order to confirm the possible synergy that was observed in plasma markers of SF exposure 
following the combination meal.  This study would ideally include multiple plasma sampling 
time-points throughout the first 24 h following consumption of the test meals.  To clarify, our 
current work identifies the plasma kinetics of total ITC appearance following consumption of 
broccoli products from 0-3 h with an additional reading at 24 h post-consumption.  Extending the 
time period to include the plasma profile of total ITC between 3 and 24 h would capture any 
further rise in plasma total ITC resulting from the myrosinase-lacking glucoraphanin powder 
meal as well as facilitate the calculation of an area under the curve for each meal.   
Next, it would be interesting to conduct an experiment at the bench to determine if glucoraphanin 
from cooked broccoli could be hydrolyzed by co-incubation with other myrosinase-containing 
vegetables such as radish, kale, horseradish or mustard.  If the results of these bench experiments 
indicate that hydrolysis of broccoli gluocraphanin does occur through the activity of other plant 
myrosinases, then conducting a feeding study in humans would be necessary to ensure the 
applicability of this finding to humans.  The novel aspect of this work would be that broccoli 
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glucoraphanin can be hydrolyzed by other plant myrosinases rather than only myrosinase from 
broccoli.  There are data supporting this hypothesis.  For example, glucoraphanin can be 
hydrolyzed by incubation with myrosinase isolated from white mustard or daikon radish (6-9).  
The application and benefit to humans would be that cooked broccoli could be combined with a 
variety of foods, rather than broccoli sprouts as the only option, for an appealing dish with added 
health benefits.    
It may also be of interest to conduct a long-term randomized controlled trial designed to 
determine whether increased dosing of SF from broccoli sprouts, glucoraphanin supplements and 
the combination of the two would result in superior protection from cancer over time.  A study 
population could be asked to consume these products 3-5 times per week and incidence of colon, 
rectum, bladder, liver, prostate, gastric, and other cancers could be followed for decades to 
definitively determine if these products reduce the incidence of cancer or impact other biological 
factors.  I think it would be fascinating to include an arm in this study where broccoli feeding 
begins at an early age, perhaps at the point when an infant progresses beyond a liquid-only diet, 
by incorporating a broccoli-based baby food into the diet.  This eating pattern would then 
continue throughout the lifetime by consuming 3-5 servings of the designated broccoli product 
weekly.  Cancer incidence and other endpoints of interest could be assessed throughout the 
lifetime.  This study design would also allow for a statement regarding the effects of consuming 
broccoli products throughout the whole lifetime rather than only later in life.  Animal studied 
could precede the clinical studies in order to save costs, generate hypotheses and assess safety.                 
Finally, because supplements for glucoraphanin are available, but are essentially ineffective 
compared to SF, I think the development of a commercialized product that utilizes preformed 
isothiocyanate, freeze-dried broccoli sprouts or glucoraphanin with a source of myrosinase for 
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use in blended beverages, cooking, etc is warranted.  However, the consumer acceptance of the 
taste and smell of such a product would need to be considered.    
 
Future work in epigenetics and broccoli 
I think the most important first step to carrying this research further is to confirm the 
demethylating effect of SF on the P21 gene using bisulfite sequencing, a state of the art 
technology that is capable of quantifying the degree and specific CpG location of changes in 
DNA methylation.  Next, this technique should be applied to explore the effects of SF on other 
genes of interest including NAD(P)H dehydrogenase, quinone 1 (NQO1), nuclear factor 
(erythroid-derived)-like 2 (NRF2), π-class glutathione S-transferase (GSTP1) and tumor protein 
p53 (P53).  The pathways of these genes are detailed in Figure 6.1.  As previously discussed, the 
Nrf2/ARE pathway is most commonly associated with the cancer risk reducing potential of 
broccoli and SF.  Of the genes listed here and examined in the research presented in this 
dissertation, only Nqo1 was reported to be affected in a Nrf2 knockout model (10).  Indeed, 
NQO1 contains an ARE sequence and is regulated by NRF2 (10).  GSTP1 also contains an ARE 
sequence and is regulated by NRF2 (11).  Therefore, the question arises as to whether the 
increases in NQO1 and GSTP1 protein caused by SF are due to traditional ARE-directed 
upregulation or if epigenetic regulation is also having an effect.  Interestingly, it was recently 
reported that Nrf2 itself was hypermethylated in a prostate cancer model and that this 
hypermethylation inhibited Nrf2 transcription (12).  Induction of Nqo1 was also inhibited in this 
hypermethylated state (12).  Restoration of Nrf2 transcription by the DNMT inhibitor 5-aza-2’-
deoxycytidine resulted in increased expression of Nrf2 and induction of Nqo1 (12).  Thus, 
epigenetic regulation of NRF2 may be of significance since the nuclear level of NRF2 protein is 
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ultimately responsible for regulation of many genes that are upregulated by SF through 
interaction with the ARE (13).  Although SF has been shown to upregulate NRF2, there are no 
studies evaluating the epigenetic effect of SF on NRF2.     
BAX, as well as P21, are controlled by the “master regulator” P53 (14).  P53 is a tumor 
suppressor gene and restoration of P53 is a promising anti-cancer strategy as it leads to apoptosis 
and cell cycle arrest (15).  P53 was reported to be upregulated by SF (16), but any involvement 
of epigenetic mechanisms was not evaluated.  Thus, it would be interesting to observe any effect 
of SF on DNA promoter methylation of the P53 gene.   
After the effects of SF on DNA methylation in HCT 116 cells are established, it would be 
extremely interesting to pursue the same study using LS123 cells.  LS123 cells are human 
colonic epithelial cells that serve as a model of pre-cancerous cells.  To elaborate, these cells are 
immortalized and abnormal, but well differentiated and non-invasive with no tumorigenic 
potential.  They have little mitotic activity and grow in confluent monolayers.  These cells are 
aneuploid and release small amounts of carcinoembryonic antigen.  Preliminary data suggest that 
several of the aforementioned genes are hypermethylated in this cell line (data not shown).  DNA 
methylation occurs early in cancer development, often preceding neoplastic transformation and 
detection of malignancy.  At early stages of cancer, when epigenetic changes are only beginning 
to be established, these genes may not be in as heavily of a repressed state as during later stages 
of cancer.  Dietary intervention may be most effective at early stages of cancer due to the fact 
that diet is a chronic and mild effector, compared to conventional chemotherapeutic methods, to 
prevent and/or slow tumor progression.  Therefore, I hypothesize that SF treatment will result in 
decreased DNA methylation and increased mRNA expression in the LS123 cell model of pre-
cancer, perhaps more robustly than in the more invasive HCT 116 cells.  This experiment would 
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provide interesting and novel information pertaining to the plasticity of DNA methylation in 
early colorectal cancer in response to SF.  
Finally, the epigenetic effects of treatment combinations with SF, particularly with lycopene or 
selenium, should be investigated.  The importance of this type of study and reasons for specific 
interest in SF combination with lycopene or selenium was discussed in section 2.6.  Unless being 
evaluated for use as a drug, all potential future research examining the epigenetic effects of 
broccoli, alone or in combination with other bioactive dietary agents, should consider including 
physiologically relevant concentrations of dietary components for the purpose of maintaining a 
study that is meaningful to the human diet.   
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Figure 6.1.  Pathways of additional tumor suppressor genes that could be evaluated in an effort to 
enhance the understanding of the effect of SF on DNA methylation.       
 
 
 
 
 
 
  
 
